Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just Voted NO to PSID Reverse/Split: 525,000 shares
Thank you for voting. Your instructions have been received and recorded for:
POSITIVEID CORPORATION
Meeting to be held on Thursday, April 18, 2013
For Shareholders of record as of Monday, March 11, 2013
CUSIP: xxxxxJ100
This confirmation has been sent from www.proxyvote.com.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PROXYVOTE.COM
You elected to receive shareholder communications and submit voting
instructions via the Internet. This e-mail notification contains
information specific to your holding in the security identified below.
Please read the instructions carefully before proceeding.
Important Notice Regarding the Availability of Proxy Materials
for the Shareholder Meeting
2013 POSITIVEID CORPORATION Special Meeting of Stockholders
MEETING DATE: April 18, 2013
For Holders as of: March 11, 2013
CUSIP NUMBER: 73740J100
ACCOUNT NUMBER: *****xxxx
CONTROL NUMBER: 70970903xxxx
You can enter your voting instructions and view the shareholder material
at the following Internet site:
http://www.proxyvote.com/070970903xxxx
For our secure site:
https://www.proxyvote.com/070970903xxxx
Note: If your E-mail software supports it, you can simply click on the
above link.
Internet voting is accepted up to 11:59 p.m. (ET) the day before the
meeting/cut off date.
To view the documents below, you may need the Adobe Acrobat Reader. To
download the Adobe Acrobat Reader, click the URL address below:
http://www.adobe.com/products/acrobat/readstep2.html
The relevant supporting documentations can also be found at the
following Internet site(s):
Proxy Statement
http://positiveidcorp.com/investors_secfilings.html
If you would like to cancel your enrollment, or change your e-mail
address please contact your Client Services representative.
There are no charges for this electronic proxy delivery service. There
may be costs associated with electronic access, such as usage charges
from Internet access providers and telephone companies, which must be
borne by the stockholder.
If you have questions, please do not reply to this e-mail. Instead,
send an e-mail from the link on your secure trading site (for security
reasons, we cannot provide account information via e-mail unless your
e-mail is sent from our secure Web site). You may also call a Client
Services representative.
TD Ameritrade, Division of TD Ameritrade, Inc., member FINRA/SIPC/NFA.
TD Ameritrade is a trademark jointly owned by TD Ameritrade IP Company,
Inc. and Toronto-Dominion Bank. Copyright 2011 TD Ameritrade IP Company,
Inc. All rights reserved. Used with permission.
Distributed by TD AMERITRADE Clearing, Inc. 1005 North Ameritrade Place,
Bellevue, NE 68005
Are-you going to re-post#6952 as a Sticky, again, as it seems like it's, exactly, what's happening with PSID..IMO
Sparky635 Tuesday, March 12, 2013 5:30:59 PM
Re: knownbrave post# 6944 Post #6952 of 7005
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85603182
NO R/S
Wanted to share this with you knownbrave from another BB? Could any of this be true? Maybe? Thoughts?
PSID has had no financing for years.
They make and sell stock daily with the aid of marketers, they have paid hundreds of thousands of dollars to over the years.
Those marketers are the ones that attract more stock buyers to replace those buyers who have lost all of their money.
They have a list of failed partnerships and teaming agreements.
Management has been very silent after a large PR pump that has lasted for quite some time.
PSID currently has very toxic financing from Ironridge and TCA global. (just research Ironridge and TCA for yourself).
Here is how it works; PSID borrows money from TCA and Iron ridge and then they pay for advertising and other business expenses.
Meanwhile TCA and Ironridge are selling PSID stock to make back there money they have lent PSID.
The whole time all of the above mentioned is going on PSID is selling their stock on the open market.
All of the shares created to “finance” operations results in dilution of price per share of PSID stock.
While good people go for a long shot the PPS falls and falls until it becomes necessary to delete the excess stock that exists on the open market.
That’s right, PSID now needs to rid itself of large amounts of stock.
The best way to do this is of course an R/S which will also increase future PPS for financing dilution.
All of the above are my own opinions. Everyone should do their own due diligence. Pay special attention to the source of the information and verify it for yourself.
Not-unrealistic for PSID-to-be one-of the-fastest and largest-moving stock-prices, as you mentioned, and said most of the movement in pps will occur by the end of 2015, as you're expecting that the movement seen in Yahoo stock price just a few years back, will be similar :)
All IMHO
That's what we're all waiting for, if not before..IMO
Your perceived PSID opinion-viewpoint appears to be correct..IMO
greaseyfingers Saturday, March 09, 2013 5:03:16 AM
Re: steltz02 post# 6792 Post #6793 of 6826
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85487044
I don't-think PSID-is-close to being-a done-deal, yet, either..IMO
Awarding of a Phase II, Stage 1 Contract Continuation will be decided upon by the outcome of a Gen-3 Analysis of Alternatives, (AoA), which was initiated by the Department of Homeland Security in July 2012, as part of the Official Required Procedure..IMO
A decision on the BioWatch Gen-3 program which is projected to be announced in the fall of 2013, following the completion of the Gen-3 Analysis of Alternatives, AoA..
Depending if this required Gen-3 Analysis of Alternatives, (AoA), decision, projected to be announced in the fall of 2013, results in a favorable, or unfavorable decision status, will determine the fate of the BioWatch Gen-3 program..IMO
This Analysis of Alternatives, (AoA), decision could end the BioWatch Gen-3 program, or delay it, or give it the green light to contiue on to the next step, Phase II, Stage 1 Contract for the scheduled 18 months of Performance Testing..IMO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Official Information from the Government's Website..
BioWatch Gen-3 Phase II, Stage 1 Presolicitation and Draft Request for Proposal
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Changed
Feb 08, 2013
1:35 pm
Solicitation Number:
HSHQDC-13-R-00026 Notice Type:
Modification/Amendment Synopsis:
Added: Feb 08, 2013 1:35 pm
The purpose of this update is to inform interested parties that posting of the draft RFP does not represent a commitment by the Government to release a final RFP or to award a contract.
The draft RFP is posted for purposes of obtaining industry comments and feedback on the proposed solicitation approach for fulfilling Phase II, Stage 1 requirements.
Award of a Phase II, Stage 1 contract will be subject to the outcome of a Gen-3 Analysis of Alternatives (AoA) initiated by the Department of Homeland Security in July 2012.
A decision on the Gen-3 program is projected in the fall of 2013 following completion of the Analysis of Alternatives, (AoA).
Please continue to monitor FedBizOpps for additional updates.
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
United States
Primary Point of Contact.:
Carla Davis,
Contracting Officer
biowatchgen3@hq.dhs.gov
https://www.fbo.gov/index?id=90399125fc575caa7b316dce773b1192
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Solicitation Number: HSHQDC-13-R-00026
Notice Type: Presolicitation
C.1.2. TWO STAGE PROCUREMENT
DHS plans to conduct a two-stage procurement for the Gen-3 Phase II acquisition using a competitive down-selection technique between stages.
Stage 1 will be for Performance Testing of candidate systems and
Stage 2 will be for Operational Test and Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2 after a competive down selection between stages.
At the conclusion of Stage 1 a separate solicitation will be issued for Stage 2 requirements.
Stage 2 will be a full and open competition.
As in Stage 1, Stage 2 offerors must also demonstrate a design maturity equivalent to that of Technology Readiness Level 7, or greater, as described in Section C.2.5. below.
In addition, they must provide an equivalent third-party data set as was generated during Stage 1.
DRAFT Request for Proposal: HSHQDC-13-R-00026
Type: Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date: January 25, 2013
HSHQDC-13-R-00026_COVER_LETTER.pdf (132.85 Kb)
Description: Cover Letter: DRAFT Request for Proposal, HSHQDC-13-R-00026
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)Download/View
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal,
HSHQDC-13-R-00026 J.1_Cost_Pricing_Schedule.xls (35.50 Kb)
Description: ATTACHMENT J.1: Cost/Pricing Schedule
J.6_Question_and_Answer_Sheet.xlsx (11.64 Kb)
Description: ATTACHMENT J.6: Draft RFP Question and Answer Sheet
J.8_NonDisclosure_Agreement.pdf (32.19 Kb)
Description: ATTACHMENT J.8: BioWatch Non-Disclosure Agreement
J.10...Subcontracting_Plan_Checklist.pdf (632.32 Kb)
Description: ATTACHMENT J.10: Small Business Subcontracting Plan Checklist
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
https://www.fbo.gov/index?s=opportunity&mode=form&id=cd3f4aa9250b9d0e77118d4d5693c2a1&tab=core&_cview=0
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Does PSID still have Northrop Grumman RuNNiN
It is a little-confusing, as-you-mentioned, in-your-post, regarding PSID
I really hope you're right, as I'd like to see PSID get the Contract..
The Sooner, The Better, so everyone's stock value can start increasing..
There seem to be so many differing opinions, viewpoints, and perceptions, as to what's actually taking place, regarding PSID..
The only thing we can really rely on for sure, is that time will tell what's going to happen..
Has-all this-PSID information been verified to-be accurate, as-presented..
Homeland Security Official Letter, dated 11-25-2012, regarding PSID..
U.S. Department of Homeland Security
Office of Procurement Operations
Washington, DC 20528
PLEASE NOTE: THIS IS A DRAFT SOLICITATION
January 25, 2013
Dear prospective offerors,
Your comments and questions are invited on attached draft Solicitation No. HSHQDC-13-R-00026.
This requirement is for the Department of Homeland Security (DHS) Office of Health Affairs (OHA), BioWatch Gen-3 Program.
This draft solicitation is for the Phase II, Stage 1 acquisition of a fully autonomous network of biodetectors that will continuously monitor the air for biothreat agents of public health concern in designated locations throughout the United States.
The acquisition will be conducted as a two-staged procurement using a competitive down-selection technique between stages.
OHA anticipates making multiple, but no more than three (3), awards under Stage 1.
Only one contract will be awarded under Stage 2 after a competitive down selection between stages.
Stage 1 is for Performance Testing of candidate systems, and will be a stand-alone contract with both firm-fixed-price and cost-reimbursement contract line items (CLINs).
Stage 2 will be for Operational Testing & Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
It will be an Indefinite Delivery Indefinite Quantity Contract.
Its resultant Task Orders will be cost-reimbursement, time and materials, and firm fixed-price.
Stage 2 will be synopsized on FedBizOpps (www.fbo.gov) in accordance with FAR 5.201 and 5.203.
Notwithstanding DHS’s expectation that only the Stage 1 contractors will be capable of successfully competing for Stage 2, all proposals will be considered.
Any other responsible source may indicate its desire to submit a proposal by responding to the Stage 2 synopsis, and DHS will provide that source a solicitation.
The NAICS code for this requirement is 811219, Other Electronic and Precision Equipment Repair and Maintenance, with the small business size standard of $19M.
The Product Service Code is J066.
The contract will have a performance period of 18 months.
Questions or issues for which you require clarification for this draft solicitation must be furnished electronically to the Contracting Officer at biowatchgen3@hq.dhs.gov.
Questions sent to any other email address or submitted via voicemail will not receive a response. No exceptions.
In order to reply to all prospective Offerors your questions for this draft solicitation must be received no later than February 11, 2013 at 10:00 AM Eastern Time.
Questions received after the due date and time will not be considered. No Exceptions.
Please ensure your subject line includes the following: “RFP Number HSHQDC-13-R-00026”. Questions and answers will be available on website www.fedbizopps.gov, entitled: “Questions and Answers”, in late February 2013. No inquiries by telephone, please.
The Government anticipates hosting an Industry Day and subsequently releasing the official and final
solicitation in the third quarter of FY 2013.
Please continue to check FedBizOpps for any updates regarding the Industry Day and posting of the final solicitation.
Thank you for your interest in the BioWatch Gen-3 requirement and we look forward to receiving your questions and comments on this
draft solicitation.
Sincerely,
Carla Davis
Contracting Officer
DRAFT Request for Proposal: HSHQDC-13-R-00026
Jan 25, 2013
HSHQDC-13-R-00026_CO...
https://www.fbo.gov/index?s=opportunity&mode=form&tab=core&id=90399125fc575caa7b316dce773b1192&_cview=0
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
greaseyfingers Tuesday, March 05, 2013 1:46:40 PM
Re: Robsct post# 6538 Post #6543 of 6795
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85309643
Information and Facts Pertaining to PSID
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal, January 25, 2013
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Solicitation Number: HSHQDC-13-R-00026
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)
Download/View HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal, HSHQDC-13-R-00026
Notice Type: Presolicitation
C.1.2. TWO STAGE PROCUREMENT
DHS plans to conduct a two-stage procurement for the Gen-3 Phase II acquisition using a competitive down-selection technique between stages.
Stage 1 will be for Performance Testing of candidate systems and
Stage 2 will be for Operational Test and Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2 after a competive down selection between stages.
At the conclusion of Stage 1 a separate solicitation will be issued for Stage 2 requirements.
Stage 2 will be a full and open competition.
As in Stage 1, Stage 2 offerors must also demonstrate a design maturity equivalent to that of Technology Readiness Level 7, or greater, as described in Section C.2.5. below.
In addition, they must provide an equivalent third-party data set as was generated during Stage 1.
DRAFT Request for Proposal: HSHQDC-13-R-00026
Type: Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date: January 25, 2013
HSHQDC-13-R-00026_COVER_LETTER.pdf (132.85 Kb)
Description: Cover Letter: DRAFT Request for Proposal, HSHQDC-13-R-00026
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)Download/View
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal,
HSHQDC-13-R-00026 J.1_Cost_Pricing_Schedule.xls (35.50 Kb)
Description: ATTACHMENT J.1: Cost/Pricing Schedule
J.6_Question_and_Answer_Sheet.xlsx (11.64 Kb)
Description: ATTACHMENT J.6: Draft RFP Question and Answer Sheet
J.8_NonDisclosure_Agreement.pdf (32.19 Kb)
Description: ATTACHMENT J.8: BioWatch Non-Disclosure Agreement
J.10...Subcontracting_Plan_Checklist.pdf (632.32 Kb)
Description: ATTACHMENT J.10: Small Business Subcontracting Plan Checklist
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
https://www.fbo.gov/index?s=opportunity&mode=form&id=cd3f4aa9250b9d0e77118d4d5693c2a1&tab=core&_cview=0
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
greaseyfingers Tuesday, March 05, 2013 7:06:59 AM
Re: Robsct post# 6487 Post #6489 of 6495
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85286818
Official Information from the Government's Website..
BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Changed
Feb 08, 2013
1:35 pm
Solicitation Number:
HSHQDC-13-R-00026 Notice Type:
Modification/Amendment Synopsis:
Added: Feb 08, 2013 1:35 pm
The purpose of this update is to inform interested parties that posting of the draft RFP does not represent a commitment by the Government to release a final RFP or to award a contract.
The draft RFP is posted for purposes of obtaining industry comments and feedback on the proposed solicitation approach for fulfilling Phase II, Stage 1 requirements.
Award of a Phase II, Stage 1 contract will be subject to the outcome of a Gen-3 Analysis of Alternatives (AoA) initiated by the Department of Homeland Security in July 2012.
A decision on the Gen-3 program is projected in the fall of 2013
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
following completion of the AoA.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Please continue to monitor FedBizOpps for additional updates.
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
United States
Primary Point of Contact.:
Carla Davis,
Contracting Officer
biowatchgen3@hq.dhs.gov
https://www.fbo.gov/index?id=90399125fc575caa7b316dce773b1192
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
greaseyfingers Friday, March 01, 2013 12:20:40 AM
Re: Robsct post# 5998 Post #6052 of 6495
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85150538
That was Then ~ This is Now
Carefully Listen to 12-26-12 SmallCapVoice.com Interview with (PSID), PositiveID Corporation's CEO, William Caragol at, http://smallcapvoice.com/blog/12-26-12-smallcapvoice-interview-with-positiveid-corporation-psid/
Positive ID's, CEO, William Caragol should be more of an expert authority, concerning PSID, than anyone else, including everyone's opinion that's on iHub..IMO
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PositveID's CEO William Caragol clearly says, in his 12-26-12 audio interview, http://smallcapvoice.com/blog/12-26-12-smallcapvoice-interview-with-positiveid-corporation-psid/, that the Request For Proposal vendor, or vendors will be chosen by DHS, to begin their Final Request For Proposal, pilot program's first phase Performance Competition Testing that's going to be announced by the end of the 3rd quarter of 2013, which would be June 30th.
This Final Request For Proposal, pilot program's first phase Competition Testing testing is projected to last throughout the remainder of 2013.
The integration of the BioWatch Generation3 program system is estimated at 3.1 billion dollars, during it's rollout over the next 5 to 6 years.
But, before this can happen, the BioWatch Generation3, Request For Propoal, chosen vendor, or vendors will have to complete the 18 months of Performance, first phase, Competion Testing.
Then, one and only one, of the competing vendors will be chosen for receiving the Final Request For Proposal Contract for the Operational, second phase Testing of the BioWatch Generation3 program.
After the Final Request For Proposal Contract for the Operational, second phase Testing of the BioWatch Generation3 program is completed in 2016.
DHS then may, upon it's discretion, implement and deploy up to 2500 BioWatch Generation Gen3 systems over the next 5 to 6 years.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The Final Request For Proposal for BioWatcj Generation 3 Performance Testing, during Stage 1, is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th.
The Stage 1 contract is expected to have a performance testing period of 18 months.
The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://investors.positiveidcorp.com/releasedetail.cfm?releaseid=738584
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Performance-testing for the current-BioWatch-Gen-3 solicitation is 18 months, during the first stage of the competition.
The procurement for BioWatch Gen-3 Phase II will occur in two stages, DHS said.
The first stage involves performance testing of proposed biodetector systems competing against each other.
The period of performance testing for the current BioWatch Gen-3 solicitation is only 18 months, during the first stage of the competition.
The second phase, of the competition, involves operational testing and evaluation as well as production, deployment, sustainment and disposal.
DHS will only be making final one award for the second-stage of the BioWatch Gen-3 Competitive Down Selection.
Hopefully, PSID will be chosen as the one, and only winner during this Final Request For Proposal Phase of The Competition..
DHS asked interested companies to submit questions on the draft RFP by Feb. 11
Consulting firm Deltek, Herndon, Va., listed BioWatch Gen-3 as the only DHS program in its top 20 federal opportunities for contractors in fiscal year 2013. BioWatch Gen-3 represents a potential $3.1 billion value over five years, according to Deltek's estimates.
The DHS Office of Health Affairs runs the BioWatch program in partnership with the Environmental Protection Agency, the FBI and the Centers for Disease Control and Prevention.
http://www.hstoday.us/focused-topics/information-technology/single-article-page/more-info-on-biowatch-3-revealed-in-draft-solicitation.html
bull_investor Sunday, February 24, 2013 12:06:53 PM
Re: colocowboy post# 5794 Post #5796 of 5917
From the GAO, (Government Accountability Office) documents.
Estimated Schedule for Key Remaining Gen-3 Deployment Steps (as of September 2012):
ADE 2B:
Q4 2013 -to- Q2 2015 -- Laboratory Performance testing
Q4 2015 -to- Q3 2016 -- Operational testing, including IT network.
ADE 3:
Q4 2016 -to- Q1 2022 -- Production of approx. 2500 Gen-3 units and phased deployment to 50 jurisdictions
Q3 2022 -- Full operational capability.
** ADE - Acquisition Decision Event
** Q - Fiscal year quarter
Source: GAO Analysis of BioWatch program documents.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84947393
bull_investor Monday, February 18, 2013 8:30:39 AM
Re: None Post #5347 of 5917
Lets Break Down the Basics (BDB)-
==> Two key terms:
1 - RFP : solicitation through bidding process, here the solicitor knows what he wants, in this RFP, everything is listed, including price, risk factors, what is achievable and what is not. This is step 1 of procurement, a sure deal. according to news release this date could be on or before June 30 2013
2 - DRAFT RFP : is not a formal solicitation tool, rather it is used to gather comments and suggestions from potential offerors. The DRFP is mandatory for all competitive acquisitions expected to exceed $25 million; it is optional for all other acquisitions. It is designed to reduce proposal preparation and evaluation time and promote a clearer understanding to industry of the requirements with a goal of a more effective and less costly contract.
Now note those "two key terms" in the Feb 6, 2013 news release:
http://investors.positiveidcorp.com/releasedetail.cfm?releaseid=738584
Title: PositiveID Reports Issuance of Draft RFP From Dept of Homeland Security for BioWatch Generation 3
PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of biological detection and diagnostics solutions, today announced that the U.S. Department of Homeland Security ("DHS") released a draft request for proposal ("RFP") for Stage 1 of BioWatch Generation 3, an autonomous biodetection system designed to protect the nation against biological threats. The final RFP for Stage 1 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th. The Stage 1 contract is expected to have a performance period of 18 months. The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707176
bull_investor Sunday, February 24, 2013 11:25:42 AM
Re: Robsct post# 5787 Post #5792 of 5917
DHS PDF says:
"The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2
after a competive down selection between stages"
It says one contract for Stage 2 - what does one contract mean??
is it one vendor? or
can a contract be of multiple vendors(PSID & NOC)?
if it is one vendor, then most likely it is PSID,
since CEO was saying that in past press releases!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84946722
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Waiting in-anticipation for PSID to win the BioWatch-Gen3-Contract
August 6, 2012 (Investorideas.com newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a news alert for biodefense stocks.
PositiveID Corporation (OTCBB: PSID) and Northrop Grumman Corporation (NYSE:NOC) as both companies prepare for technology acquisitions and procurement for BioWatch Generation 3 this fall.
In July 2012, Northrop Grumman Corporation (NYSE:NOC) reported that its Next Generation Automated Detection System (NG-ADS) for homeland defense applications has successfully completed a rigorous field test and is ready for the program's next phase.
The NG-ADS technology is a competitor for the Department of Homeland Security's (DHS) upcoming BioWatch Gen-3 Phase II acquisition.
The program seeks to deploy a nationwide network of fully autonomous bio-detectors in major metropolitan areas across the United States to provide early warning of a biological attack. DHS recently announced that a request for proposals will be issued later this year.
The request for proposal got postponed by DHS, as we all know, into 2013.
As a fully automated biological detection system, the NG-ADS continuously collects air samples, analyzes the samples for the presence of multiple biological pathogens, and automatically reports results to public health officials multiple times each day through a secure data network.
More than 20,000 samples were collected and analyzed during the recent field test in a variety of indoor and outdoor locations in a major city in the United States .
"There are concerns that our nation won't be ready to respond should a biological attack occur," said Dave Tilles, director of Homeland Security programs at Northrop Grumman's Electronic Systems sector.
"Early warning provided by an automated detection system such as the NG-ADS will allow the nation's public health and public safety officials to proactively manage the response to a biological event to reduce exposure and treat the affected population to minimize casualties."
Since the successful field test, additional improvements have been made to the NG-ADS to enhance the system's performance while reducing its life-cycle cost.
The proven, life-saving capability of the NG-ADS draws upon Northrop Grumman's decade long experience developing, testing, deploying, and operating bio-detection systems for the U.S. government and other customers.
PositiveID Corporation (OTCBB: PSID) recently reported it added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems ("MFS") subsidiary. The Company will utilize Dr. Smith's expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security ("DHS") for BioWatch Generation 3, a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America 's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. www.PositiveIDCorp.com.
http://www.investorideas.com/news/2012/main/08062.asp
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
greaseyfingers Friday, March 01, 2013 1:24:03 AM
Re: Robsct post# 5388 Post #6053 of 6495
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85151869
Getting the facts straight ~ regarding PSID..
It appears you have good intentions ~ but most seem to be questioning your opinion ~ even the website links you're providing are in contradiction of the actual facts concerning PSID..
The information you're website link is referring to, is from (June 2007)
The program was kicked off in 2007 and said to be scheduled for testing in 2008 with completion of the whole program between 2009 and 2012.
It Says, "BioWatch 3 is expected to be pilot tested in fiscal year 2008 and fully deployed between fiscal years 2009 and 2012."
http://www.dhs.gov/lab-box
However, this official time frame testing never happened, during the lime line, as was first projected by the government's DHS.
The government's Department of Homeland Security kept postponing it, from occurring, each and every year, until allowing their Final Draft Request For Proposal Competition Testing, for Stage 1 Performance Testing, and Stage 2 Operational Testing, to start proceeding forward, as the first stage is doing, now.
makingbiigdough Monday, February 18, 2013 11:08:02 AM
Re: Robsct post# 5351 Post #5368 of 5378
Rob you are right BUT also wrong! This is a WHOLE NEW PROCUREMENT! Yes you are correct we are in Phase II, however we are at stage I. My wife suggest we ALL need to talk less and read MORE! Lol
The GREAT News is that we are VERY close to the DHS releasing of the FINAL RFP!! I beleieve that by the 2nd week of March at the latest! Could happen MUCH sooner guys! JMO
After RFP is released than we can expect a contract award being issued for multiple contracts for a firm fixed amount, as well as cost re-imbursement! This should imo happen within 2-4wks after RFP!
Also there just might not be an industry day, if so it will be just a formality, just as with the DRFP! Will NOT have any significance at all per my wife! She was confident in saying that RFP could be released at anytime! Gotta run guys hope this helps! Don't STRESS remain PATIENT we are VERY close my friends!
My wife from her experience working for DoD for MANY years says with the UPMOST CONFIDENCE that PSID hands down will be chosen for 1 of the multiple contract awards being awarded in STAGE I!
Her final conclusion is that PSID like Coca Cola is a stock you don't eat on or have to pay your rent with! What she means is IT is going to happen, but be able to pay your bills in the meantime! Remember it is a LONG GREVIOUS process anytime you are dealing with our GOV!!
I once again think it is sooner than later! Gotta run take care everyone! MBD
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84709677
Davecatchndawave Monday, February 18, 2013 9:08:10 AM
Re: A deleted message Post #5352 of 5374
I want to believe this. I am having trouble with the fact that Caragol's PR doesn't jive with you. Can you explain the psid PR?
psid PR feb 6
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707630
bull_investor Monday, February 18, 2013 11:40:18 AM
Re: makingbiigdough post# 5368 Post #5379 of 5388
Rob-
IMO,focus on getting your post correct before calling others misleading.
No offence meant! back to relax mode.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84710325
sayuncle Monday, February 18, 2013 8:43:26 AM
Re: Robsct post# 5336 Post #5349 of 5400
I think the last post by Bull Investor clears it up accurately in stating that we are still in that 18 month waiting game which will begin after June 30th.
I read both links again and came to that same conclusion.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707319
greaseyfingers Sunday, February 17, 2013 10:23:37 PM
Re: None Post #5335 of 5400
Performance-testing for the current-BioWatch-Gen-3 solicitation is 18 months, during the first stage of the competition.
The procurement for BioWatch Gen-3 Phase II will occur in two stages, DHS said.
The first stage involves performance testing of proposed biodetector systems competing against each other.
The period of performance testing for the current BioWatch Gen-3 solicitation is only 18 months, during the first stage of the competition.
The second phase, of the competition, involves operational testing and evaluation as well as production, deployment, sustainment and disposal.
DHS will only be making final one award for the second-stage of the BioWatch Gen-3 Competitive Down Selection.
Hopefully, PSID will be chosen as the one, and only winner during this Final Request For Proposal Phase of The Competition..
DHS asked interested companies to submit questions on the draft RFP by Feb. 11
Consulting firm Deltek, Herndon, Va., listed BioWatch Gen-3 as the only DHS program in its top 20 federal opportunities for contractors in fiscal year 2013. BioWatch Gen-3 represents a potential $3.1 billion value over five years, according to Deltek's estimates.
The DHS Office of Health Affairs runs the BioWatch program in partnership with the Environmental Protection Agency, the FBI and the Centers for Disease Control and Prevention.
http://www.hstoday.us/focused-topics/information-technology/single-article-page/more-info-on-biowatch-3-revealed-in-draft-solicitation.html
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PositiveID has clearly stated the specific timeline information for the BioWatch Generation 3, stage 1 performance testing phase, in their February 6, 2013 PositiveID Reports Issuance of Draft RFP From Dept of Homeland Security for BioWatch Generation 3, if you read it very closely.
It Specifically Says,
"The final RFP for Stage 1 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th."
"The Stage 1 contract is expected to have a performance period of 18 months. The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years."
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~Information which was published by PositveID for investors and to whom it may concern.
Clearly indicates and specifys that the BioWatch Generation 3 final Request For Proposal for stage 1 performance testing phase is going to be released, sometime, in the government's third quarter of fiscal 2013, which ends June 30th.
Once that event takes place, as they clearly specify.
Then, The Stage 1 contract is expected to have a performance period of 18 months.
http://investors.positiveidcorp.com/releasedetail.cfm?ReleaseID=738584
Read-Posts #6602, #6608, #6609, and #6692 and-formulate-your-own PSID-opinion..
Post #6602
BioWatch consumes the majority of OHA's $166.46 million fiscal 2013 request, with DHS requesting Congress approve new budget authority of $125.29 million.
According to the fiscal 2013 DHS budget justification (large .pdf), OHA plans on performing an operational test and evaluation of Gen-3 sensors in four U.S. cities.
Read more: BioWatch Gen-3 behind schedule - FierceHomelandSecurity
http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0#ixzz2MvT3BPE6
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85335854
~~~~~~~~~~~~~~~~~~~~
Post #6608
Filed-Under Alexander Garza, biodefense, bioterrorism, BioWatch, counterterrorism, fiscal-2013, House Homeland Security, Office of Health Affairs..
Therefore this information which was posted on FierceHomelandSecurity's Website, saying it's for fiscal year 2013, wouldn't be outdated, according their info..IMO
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85337634
www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0
~~~~~~~~~~~~~~~~~~~~
Post #6609
Changed
Feb 08, 2013
1:35 pm
Solicitation Number:
HSHQDC-13-R-00026 Notice Type:
Award-of-Phase II, Stage-1 Contract, subject to Gen-3 Analysis-of-Alternatives.. [/color]
Unless DHS specifically defines for everyone, to whom it may concern, what the exact legal definition meaning is of their terminology phrase, Gen-3 Analysis of Alternatives, (AoA), actually means..
It leaves room for speculation, in the meantime, until we are Officially Informed.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85337849
~~~~~~~~~~~~~~~~~~~~
Post #6692
DHS-faces $3.2B in sequestration-cuts ~ March 4, 2013
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85382740
www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0
~~~~~~~~~~~~~~~~~~~~
I don't-think PSID-is-close to being-a done-deal, yet, either..IMO
Awarding of a Phase II, Stage 1 contract will be decided upon by the outcome of a Gen-3 Analysis of Alternatives, (AoA), which was initiated by the Department of Homeland Security in July 2012, as part of the Official Required Procedure..
A decision on the Gen-3 program which is projected to be announced in the fall of 2013, following the completion of the Gen-3 Analysis of Alternatives, AoA..
Depending if this required Gen-3 Analysis of Alternatives, (AoA), decision, projected to be announced in the fall of 2013, results in a favorable, or unfavorable decision status, will determine the fate of the BioWatch Gen-3 program..IMO
This Analysis of Alternatives, (AoA), decision could end the BioWatch Gen-3 program, or delay it, or give it the green light to contiue on to the next step, Phase II, Stage 1 Contract for the scheduled 18 months of Performance Testing..IMO
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Official Information from the Government's Website..
BioWatch Gen-3 Phase II, Stage 1 Presolicitation and Draft Request for Proposal
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Changed
Feb 08, 2013
1:35 pm
Solicitation Number:
HSHQDC-13-R-00026 Notice Type:
Modification/Amendment Synopsis:
Added: Feb 08, 2013 1:35 pm
The purpose of this update is to inform interested parties that posting of the draft RFP does not represent a commitment by the Government to release a final RFP or to award a contract.
The draft RFP is posted for purposes of obtaining industry comments and feedback on the proposed solicitation approach for fulfilling Phase II, Stage 1 requirements.
Award of a Phase II, Stage 1 contract will be subject to the outcome of a Gen-3 Analysis of Alternatives (AoA) initiated by the Department of Homeland Security in July 2012.
A decision on the Gen-3 program is projected in the fall of 2013 following completion of the Analysis of Alternatives, (AoA).
Please continue to monitor FedBizOpps for additional updates.
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
United States
Primary Point of Contact.:
Carla Davis,
Contracting Officer
biowatchgen3@hq.dhs.gov
https://www.fbo.gov/index?id=90399125fc575caa7b316dce773b1192
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Solicitation Number: HSHQDC-13-R-00026
Notice Type: Presolicitation
C.1.2. TWO STAGE PROCUREMENT
DHS plans to conduct a two-stage procurement for the Gen-3 Phase II acquisition using a competitive down-selection technique between stages.
Stage 1 will be for Performance Testing of candidate systems and
Stage 2 will be for Operational Test and Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2 after a competive down selection between stages.
At the conclusion of Stage 1 a separate solicitation will be issued for Stage 2 requirements.
Stage 2 will be a full and open competition.
As in Stage 1, Stage 2 offerors must also demonstrate a design maturity equivalent to that of Technology Readiness Level 7, or greater, as described in Section C.2.5. below.
In addition, they must provide an equivalent third-party data set as was generated during Stage 1.
DRAFT Request for Proposal: HSHQDC-13-R-00026
Type: Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date: January 25, 2013
HSHQDC-13-R-00026_COVER_LETTER.pdf (132.85 Kb)
Description: Cover Letter: DRAFT Request for Proposal, HSHQDC-13-R-00026
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)Download/View
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal,
HSHQDC-13-R-00026 J.1_Cost_Pricing_Schedule.xls (35.50 Kb)
Description: ATTACHMENT J.1: Cost/Pricing Schedule
J.6_Question_and_Answer_Sheet.xlsx (11.64 Kb)
Description: ATTACHMENT J.6: Draft RFP Question and Answer Sheet
J.8_NonDisclosure_Agreement.pdf (32.19 Kb)
Description: ATTACHMENT J.8: BioWatch Non-Disclosure Agreement
J.10...Subcontracting_Plan_Checklist.pdf (632.32 Kb)
Description: ATTACHMENT J.10: Small Business Subcontracting Plan Checklist
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
https://www.fbo.gov/index?s=opportunity&mode=form&id=cd3f4aa9250b9d0e77118d4d5693c2a1&tab=core&_cview=0
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Award-of-Phase II, Stage-1 Contract, subject to Gen-3 Analysis-of-Alternatives..
Unless DHS specifically defines for everyone, to whom it may concern, what the exact legal definition meaning is of their terminology phrase, Gen-3 Analysis of Alternatives, (AoA), actually means..
It leaves room for speculation, in the meantime, until we are Officially Informed..
greaseyfingers Tuesday, March 05, 2013 7:06:59 AM
Re: Robsct post# 6487 Post #6489 of 6699
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85286818
Official Information from the Government's Website..
BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Changed
Feb 08, 2013
1:35 pm
Solicitation Number:
HSHQDC-13-R-00026 Notice Type:
Modification/Amendment Synopsis:
Added: Feb 08, 2013 1:35 pm
The purpose of this update is to inform interested parties that posting of the draft RFP does not represent a commitment by the Government to release a final RFP or to award a contract.
The draft RFP is posted for purposes of obtaining industry comments and feedback on the proposed solicitation approach for fulfilling Phase II, Stage 1 requirements.
Award of a Phase II, Stage 1 contract will be subject to the outcome of a Gen-3 Analysis of Alternatives (AoA) initiated by the Department of Homeland Security in July 2012.
A decision on the Gen-3 program is projected in the fall of 2013
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
following completion of the Analysis of Alternatives, (AoA).
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Please continue to monitor FedBizOpps for additional updates.
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
United States
Primary Point of Contact.:
Carla Davis,
Contracting Officer
biowatchgen3@hq.dhs.gov
https://www.fbo.gov/index?id=90399125fc575caa7b316dce773b1192
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Solicitation Number: HSHQDC-13-R-00026
Notice Type: Presolicitation
C.1.2. TWO STAGE PROCUREMENT
DHS plans to conduct a two-stage procurement for the Gen-3 Phase II acquisition using a competitive down-selection technique between stages.
Stage 1 will be for Performance Testing of candidate systems and
Stage 2 will be for Operational Test and Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2 after a competive down selection between stages.
At the conclusion of Stage 1 a separate solicitation will be issued for Stage 2 requirements.
Stage 2 will be a full and open competition.
As in Stage 1, Stage 2 offerors must also demonstrate a design maturity equivalent to that of Technology Readiness Level 7, or greater, as described in Section C.2.5. below.
In addition, they must provide an equivalent third-party data set as was generated during Stage 1.
DRAFT Request for Proposal: HSHQDC-13-R-00026
Type: Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date: January 25, 2013
HSHQDC-13-R-00026_COVER_LETTER.pdf (132.85 Kb)
Description: Cover Letter: DRAFT Request for Proposal, HSHQDC-13-R-00026
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)Download/View
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal,
HSHQDC-13-R-00026 J.1_Cost_Pricing_Schedule.xls (35.50 Kb)
Description: ATTACHMENT J.1: Cost/Pricing Schedule
J.6_Question_and_Answer_Sheet.xlsx (11.64 Kb)
Description: ATTACHMENT J.6: Draft RFP Question and Answer Sheet
J.8_NonDisclosure_Agreement.pdf (32.19 Kb)
Description: ATTACHMENT J.8: BioWatch Non-Disclosure Agreement
J.10...Subcontracting_Plan_Checklist.pdf (632.32 Kb)
Description: ATTACHMENT J.10: Small Business Subcontracting Plan Checklist
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
https://www.fbo.gov/index?s=opportunity&mode=form&id=cd3f4aa9250b9d0e77118d4d5693c2a1&tab=core&_cview=0
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Robsct Tuesday, March 05, 2013 5:19:45 AM
Re: None Post #6487 of 6488
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85285694
I'll post this again. According to DHS's timetable they want to award the big contract to produce and deploy Gen-3 this year.
The program was kicked off in 2007 and said to be scheduled for testing in 2008 with completion of the whole program in 2012. The article identifies the division of DHS as the same one that Caragol stated in the recent PR. It's the same testing phase...and it's now done.
"This is the two-pronged goal of research behind the Generation 3 BioWatch Program, which is funded by the Chemical and Biological Division at the Department of Homeland Security's (DHS) Science and Technology Directorate (S&T). "
http://www.dhs.gov/lab-box
"William J. Caragol, Chairman and CEO of PositiveID, stated, "We believe that PositiveID is well positioned for BioWatch Generation 3, as our M-BAND detection technology (Microfluidics-based BioAgent Autonomous Networked Detector) was the only system of its kind successfully demonstrated in the field as part of the DHS Science & Technology Directorate ("S&T") BAND (BioAgent Autonomous Networked Detector) Program. In October 2012, we issued a corporate update to our stockholders about the BioWatch program, stating that we were in discussions with strategic partners to manufacture and sell M-BAND, and reiterating our belief that the BioWatch program would soon begin to roll out."
http://finance.yahoo.com/news/positiveid-reports-issuance-draft-rfp-213000044.html
Link you're requesting was already within previous post, http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0, if you had scrolled down to see it..
Now, you can check out the actual website's information which was posted, if you feel inclined to do so..
greaseyfingers Thursday, March 07, 2013 8:19:12 AM
Re: Robsct post# 6696 Post #6698 of 6698
Relieved to hear Sequestration won't-cut any-current BioWatch-Gen3 spending, as you mentioned..
greaseyfingers Wednesday, March 06, 2013 5:54:52 AM
Re: None Post #6602 of 6697
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85335854
DHS-requesting Congress-approve new-BioWatch Gen3 budget of $125.29 million..
BioWatch consumes the majority of OHA's $166.46 million fiscal 2013 request, with DHS requesting Congress approve new budget authority of $125.29 million.
According to the fiscal 2013 DHS budget justification (large .pdf), OHA plans on performing an operational test and evaluation of Gen-3 sensors in four U.S. cities.
But Garza, during the hearing, said that only one company's product has so far made it through the first phase of Gen-3 procurement.
(Operational testing constitutes the program's second phase), and said he can "make no guarantees that it'll make it through the next phase of testing."
He said the program has run into scheduling difficulties because the technology required for Gen-3 is cutting edge.
Whether or not the Gen-3 schedule has slipped is a matter of perspective, Garza argued.
"It depends if you're looking at the acquisition timeline or if you're looking at 'Hey, this is a new technology,'" he said.
"If you look at the acquisition timeline, it's slipped--absolutely, it's slipped," he added.
For more:
- go to the hearing webpage (prepared testimony and webcast available)
Related Articles:
DHS downgrades NBAF risk
Uncertainty around BioShield funding
Feds urge state and local stockpiling of anti-anthrax antibiotics
Sign up for our free newsletter
Read more: BioWatch Gen-3 behind schedule - FierceHomelandSecurity
http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0#ixzz2MkpAHrR3
Subscribe: http://www.fiercehomelandsecurity.com/signup?sourceform=Viral-Tynt-FierceHomelandSecurity-FierceHomelandSecurity
http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0
Filed UnderAlexander Garza, biodefense, bioterrorism, BioWatch, counterterrorism, fiscal 2013, House Homeland Security, Office of Health Affairs
Read more: BioWatch Gen-3 behind schedule - FierceHomelandSecurity
http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0#ixzz2Mkr9LeGm
Subscribe: http://www.fiercehomelandsecurity.com/signup?sourceform=Viral-Tynt-FierceHomelandSecurity-FierceHomelandSecurity
DRAFT Request for Proposal: HSHQDC-13-R-00026
Type: Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Label: Draft Request for Proposal: HSHQDC-13-R-00026
Posted Date: January 25, 2013
Original Synopsis
Presolicitation
Jan 25, 2013
12:42 pm
Changed
Feb 08, 2013
1:35 pm
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
greaseyfingers Wednesday, March 06, 2013 4:07:49 AM
Re: colocowboy post# 6589 Post #6598 of 6604
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85335024
DRAFT Request for Proposal: HSHQDC-13-R-00026
Type: Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Label: Draft Request for Proposal: HSHQDC-13-R-00026
Posted Date: January 25, 2013
Original Synopsis
Presolicitation
Jan 25, 2013
12:42 pm
Changed
Feb 08, 2013
1:35 pm
~~~~~~~~~~~~~~~~~~~~~
Two-Stage BioWatch Gen-3 Procurement Using Competitive Down-Selection Procedures..
C.1.2. TWO STAGE PROCUREMENT
HSHQDC-13-R-00026 (page 5)
DHS plans to conduct a two-stage procurement for the Gen-3 Phase II acquisition using a competitive down-selection technique between stages.
Stage 1 will be for Performance Testing of candidate systems.
And Stage 2 will be for Operational Test and Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2 after a competive down selection between stages.
At the conclusion of Stage 1 a separate solicitation will be issued for Stage 2 requirements.
Stage 2 will be a full and open competition.
As in Stage 1, Stage 2 offerors must also demonstrate a design maturity equivalent to that of Technology Readiness Level 7, or greater, as described in Section C.2.5. below.
In addition, they must provide an equivalent third-party data set as was generated during Stage 1.
C.2. PURPOSE
The purpose of this acquisition is to obtain a fully autonomous networked biodetection capability (known as Generation 3 or Gen-3) that will be deployed, operated, and sustained, both indoor and outdoor, in selected US BioWatch jurisdictions throughout the United States to continuously monitor the air for agents of biological concern.
This requirement supports the DHS plan to increase the capability of the BioWatch system by augmenting and ultimately replacing the current collection and biodetection capability with an autonomous biodetection capability that will improve timeliness, time resolution, population coverage, and cost effectiveness while enabling the program to stay within its fiscal constraints.
C.2.1. Scope
Under the Phase II Stage 1 contract, the Contractor shall provide their candidate automated detection system, subsystems, and all technical support to enable the Government to test in laboratory settings to determine the adequacy of the candidate system for future procurement and deployment.
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)
Download/View HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal, HSHQDC-13-R-00026
https://www.fbo.gov/index?s=opportunity&mode=form&id=90399125fc575caa7b316dce773b1192&tab=core&_cview=1
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
L.3 Two Stage Procurement Using Down-Selection Procedures. (page 73)
This solicitation is for the BioWatch Gen-3 Phase II, Stage 1 acquisition to provide a fully autonomous network of biodetectors that will continuously monitor the air for biothreat agents of public health concern in designated locations throughout the United States.
The acquisition will be conducted as a two-staged procurement.
(also reference section C.1, Two Stage Procurement) using a competitive down-selection technique between stages.
DHS anticipates making multiple, but no more than three (3) awards under Stage 1.
Only one contract will be awarded under Stage 2 after a competitive down selection between stages.
This current acquisition, Stage 1, is for Performance Testing of candidate systems, and will be a stand-alone cost-reimbursement and firm-fixed-price contract.
Stage 2 will be for Operational Testing & Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
It will be an Indefinite Delivery Indefinite Quantity Contract.
Its resultant Task Orders will be cost reimbursement, time and materials, and firm fixed-price.
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)
Download/View HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal, HSHQDC-13-R-00026
https://www.fbo.gov/index?s=opportunity&mode=form&id=90399125fc575caa7b316dce773b1192&tab=core&_cview=1
The full text of a solicitation provision may be accessed electronically at this address: http://www.acquisition.gov
SECTION G – CONTRACT ADMINISTRATION DATA (page 26)
G.1. CONTRACTING OFFICER
The Contracting Officer for this Contract is identified below:
Name: Carla Davis
Title: Contracting Officer
Agency: DHS - Office of Procurement Operations
Address: 245 Murray Lane, SW
Mailstop 0115
Washington, DC 20528-0115
Voice: TBD
Email: TBD
G.3. CONTRACTING OFFICER’S AUTHORITY
The Contracting Officer (CO) assigned to this contract has responsibility for ensuring the performance of all necessary actions for effective contracting; ensuring compliance with the terms of the contract and safeguarding the interests of the United States in its contractual relationships.
The Contracting Officer (CO) is the only individual who has the authority to enter into, administer, or terminate this contract and is the only person authorized to approve changes to any of the requirements under this contract, and notwithstanding any provision contained elsewhere in this contract, this authority remains solely with the CO.
It is the Contractor’s responsibility to contact the CO immediately if there is even the appearance of any technical direction that is or may be outside the scope of the contract.
The Government will not reimburse the Contractor for any work not authorized by the CO, including work outside the scope of the contract.
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)
Download/View HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal, HSHQDC-13-R-00026
https://www.fbo.gov/index?s=opportunity&mode=form&id=90399125fc575caa7b316dce773b1192&tab=core&_cview=1
Filed-Under Alexander Garza, biodefense, bioterrorism, BioWatch, counterterrorism, fiscal-2013, House Homeland Security, Office of Health Affairs..
Therefore this information which was posted on FierceHomelandSecurity's Website, saying it's for fiscal year 2013, shouldn't be outdated, according their info..IMO
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
greaseyfingers Wednesday, March 06, 2013 5:54:52 AM
Re: None Post #6602 of 6605
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85335854
DHS-requesting Congress-approve new-BioWatch Gen3 budget of $125.29 million..
BioWatch consumes the majority of OHA's $166.46 million fiscal 2013 request, with DHS requesting Congress approve new budget authority of $125.29 million.
According to the fiscal 2013 DHS budget justification (large .pdf), OHA plans on performing an operational test and evaluation of Gen-3 sensors in four U.S. cities.
But Garza, during the hearing, said that only one company's product has so far made it through the first phase of Gen-3 procurement.
(Operational testing constitutes the program's second phase), and said he can "make no guarantees that it'll make it through the next phase of testing."
He said the program has run into scheduling difficulties because the technology required for Gen-3 is cutting edge.
Whether or not the Gen-3 schedule has slipped is a matter of perspective, Garza argued.
"It depends if you're looking at the acquisition timeline or if you're looking at 'Hey, this is a new technology,'" he said.
"If you look at the acquisition timeline, it's slipped--absolutely, it's slipped," he added.
For more:
- go to the hearing webpage (prepared testimony and webcast available)
Related Articles:
DHS downgrades NBAF risk
Uncertainty around BioShield funding
Feds urge state and local stockpiling of anti-anthrax antibiotics
Sign up for our free newsletter
Read more: BioWatch Gen-3 behind schedule - FierceHomelandSecurity
http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0#ixzz2MkpAHrR3
Subscribe: http://www.fiercehomelandsecurity.com/signup?sourceform=Viral-Tynt-FierceHomelandSecurity-FierceHomelandSecurity
http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0
Filed Under Alexander Garza, biodefense, bioterrorism, BioWatch, counterterrorism, fiscal 2013, House Homeland Security, Office of Health Affairs
Read more: BioWatch Gen-3 behind schedule - FierceHomelandSecurity
http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0#ixzz2Mkr9LeGm
Subscribe: http://www.fiercehomelandsecurity.com/signup?sourceform=Viral-Tynt-FierceHomelandSecurity-FierceHomelandSecurity
DHS-requesting Congress-approve new-BioWatch Gen3 budget of $125.29 million..
BioWatch consumes the majority of OHA's $166.46 million fiscal 2013 request, with DHS requesting Congress approve new budget authority of $125.29 million.
According to the fiscal 2013 DHS budget justification (large .pdf), OHA plans on performing an operational test and evaluation of Gen-3 sensors in four U.S. cities.
But Garza, during the hearing, said that only one company's product has so far made it through the first phase of Gen-3 procurement.
(Operational testing constitutes the program's second phase), and said he can "make no guarantees that it'll make it through the next phase of testing."
He said the program has run into scheduling difficulties because the technology required for Gen-3 is cutting edge.
Whether or not the Gen-3 schedule has slipped is a matter of perspective, Garza argued.
"It depends if you're looking at the acquisition timeline or if you're looking at 'Hey, this is a new technology,'" he said.
"If you look at the acquisition timeline, it's slipped--absolutely, it's slipped," he added.
For more:
- go to the hearing webpage (prepared testimony and webcast available)
Related Articles:
DHS downgrades NBAF risk
Uncertainty around BioShield funding
Feds urge state and local stockpiling of anti-anthrax antibiotics
Sign up for our free newsletter
Read more: BioWatch Gen-3 behind schedule - FierceHomelandSecurity
http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0#ixzz2MkpAHrR3
Subscribe: http://www.fiercehomelandsecurity.com/signup?sourceform=Viral-Tynt-FierceHomelandSecurity-FierceHomelandSecurity
http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0
Filed UnderAlexander Garza, biodefense, bioterrorism, BioWatch, counterterrorism, fiscal 2013, House Homeland Security, Office of Health Affairs
Read more: BioWatch Gen-3 behind schedule - FierceHomelandSecurity
http://www.fiercehomelandsecurity.com/story/biowatch-gen-3-behind-schedule/2012-04-02-0#ixzz2Mkr9LeGm
Subscribe: http://www.fiercehomelandsecurity.com/signup?sourceform=Viral-Tynt-FierceHomelandSecurity-FierceHomelandSecurity
Biothreat-Detection-Stocks Aim-for Homeland-Security’s $3 Billion BioWatch Gen-3 Prize
Older Information that's good for PSID uPSIDe Morale..
Much of the American public along with investors have probably forgotten about the 2001 anthrax attacks but a handful of stocks, including PositiveID Corporation (OTC: PSID), Northrop Grumman Corporation (NYSE: NOC) and Cepheid (NASDAQ: CPHD), have developed biothreat detection technologies that will hopefully prevent further bioterrorism or biowarfare attacks.
Its also worth noting that two of these companies, PositiveID Corporation (PSID) and Northrop Grumman Corporation (NOC), are hoping to be suppliers for the Department of Homeland Security’s (DHS) BioWatch Gen-3 program which is worth $3 billion over five years.
Starting with PositiveID Corporation, it’s a medical device company involved in the development of medical devices and molecular diagnostic systems for diabetes management plus rapid medical testing and airborne biothreat detection.
On the biothreat detection side of the business, PositiveID Corporation’s MicroFluidic Systems (MFS) subsidiary is considered to be a leader in biothreat detection technologies and molecular diagnostic systems.
In fact, it has already received $45 million in government and commercial contracts over the past ten years plus it has a strong IP portfolio of 29 patents or patents pending.
Moreover and under contract from the Department of Homeland Security (DHS) over the past eight years, MicroFluidic Systems (MFS) has developed M-BAND technology – a so-called a Microfluidics-based Bioagent Autonomous Networked Detector that will scan the air for bio-warfare agents (e.g. anthrax) and operate on its own for as long as 30 days.
More importantly and should PositiveID Corporation secure supplier status for its M-BAND technology (decisions will likely be made in 3Q2012), postponed to 2013, investors have a good reason to be excited given how much the program is worth.
The profit margins are expected to be in the 15% to 20% plus other government agencies like the Army will no doubt also want to acquire the devices.
In addition to the M-BAND technology, PositiveID Corporation’s Dragonfly(TM) Rapid MDx Cartridge-based diagnostic system is designed to be a miniaturized point-of-care or field based system that has the ability to perform molecular diagnostic results from a sample in less than 30 minutes.
Specifically, Dragonfly(TM) is effective at detecting a whole range of pathogens, including influenza, E. coli and methicillin-resistant staphylococcus aureus (MRSA), along with detecting radiation-induced cell damage.
Meanwhile, defense industry behemoth Northrop Grumman Corporation (NYSE: NOC) reported about a year ago that it was field testing its own biodetector technology for the BioWatch Gen-3 program.
Plus, it has already delivered important assay technology to the DHS.
However, I am not seeing any further updates from the company regarding field testing or deliveries.
Finally, its also worth briefly mentioning Cepheid (NASDAQ: CPHD), a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market plus for applications in non-clinical biothreat, industrial and partner markets.
On the biothreat front, Cepheid has developed tests that are designed for the surveillance of anthrax agents in environmental samples.
However, Cepheid’s main focus is still products for the healthcare market rather than the biodetection market.
I should also mention that late today, Cepheid will be releasing 1Q2012 earnings and that after 4Q2011 earnings were reported, the stock shot up 27% as the company trounced Wall Street’s expectations.
The Bottom Line. With the $3 billion DHS BioWatch Gen-3 program set to be awarded, investors and traders alike should keep an eye on PositiveID Corporation (PSID).
http://www.smallcapnetwork.com/Biothreat-Detection-Stocks-Aim-for-Homeland-Security-s-3-Billion-BioWatch-Gen-3-Prize-PositiveID-Corporation-PSID-Northrop-Grumman-Corporation-NOC-Cepheid-CPHD/s/via/3414/article/view/p/mid/1/id/638/
Two-Stage BioWatch Gen-3 Procurement Using Competitive Down-Selection Procedures..
C.1.2. TWO STAGE PROCUREMENT
HSHQDC-13-R-00026 (page 5)
DHS plans to conduct a two-stage procurement for the Gen-3 Phase II acquisition using a competitive down-selection technique between stages.
Stage 1 will be for Performance Testing of candidate systems.
And Stage 2 will be for Operational Test and Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2 after a competive down selection between stages.
At the conclusion of Stage 1 a separate solicitation will be issued for Stage 2 requirements.
Stage 2 will be a full and open competition.
As in Stage 1, Stage 2 offerors must also demonstrate a design maturity equivalent to that of Technology Readiness Level 7, or greater, as described in Section C.2.5. below.
In addition, they must provide an equivalent third-party data set as was generated during Stage 1.
C.2. PURPOSE
The purpose of this acquisition is to obtain a fully autonomous networked biodetection capability (known as Generation 3 or Gen-3) that will be deployed, operated, and sustained, both indoor and outdoor, in selected US BioWatch jurisdictions throughout the United States to continuously monitor the air for agents of biological concern.
This requirement supports the DHS plan to increase the capability of the BioWatch system by augmenting and ultimately replacing the current collection and biodetection capability with an autonomous biodetection capability that will improve timeliness, time resolution, population coverage, and cost effectiveness while enabling the program to stay within its fiscal constraints.
C.2.1. Scope
Under the Phase II Stage 1 contract, the Contractor shall provide their candidate automated detection system, subsystems, and all technical support to enable the Government to test in laboratory settings to determine the adequacy of the candidate system for future procurement and deployment.
https://www.fbo.gov/index?s=opportunity&mode=form&id=90399125fc575caa7b316dce773b1192&tab=core&_cview=1
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
L.3 Two Stage Procurement Using Down-Selection Procedures. (page 73)
This solicitation is for the BioWatch Gen-3 Phase II, Stage 1 acquisition to provide a fully autonomous network of biodetectors that will continuously monitor the air for biothreat agents of public health concern in designated locations throughout the United States.
The acquisition will be conducted as a two-staged procurement.
(also reference section C.1, Two Stage Procurement) using a competitive down-selection technique between stages.
DHS anticipates making multiple, but no more than three (3) awards under Stage 1.
Only one contract will be awarded under Stage 2 after a competitive down selection between stages.
This current acquisition, Stage 1, is for Performance Testing of candidate systems, and will be a stand-alone cost-reimbursement and firm-fixed-price contract.
Stage 2 will be for Operational Testing & Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
It will be an Indefinite Delivery Indefinite Quantity Contract.
Its resultant Task Orders will be cost reimbursement, time and materials, and firm fixed-price.
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)
Download/View HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal, HSHQDC-13-R-00026
https://www.fbo.gov/index?s=opportunity&mode=form&id=90399125fc575caa7b316dce773b1192&tab=core&_cview=1
The full text of a solicitation provision may be accessed electronically at this address: http://www.acquisition.gov
SECTION G – CONTRACT ADMINISTRATION DATA(page 26)
G.1. CONTRACTING OFFICER
The Contracting Officer for this Contract is identified below:
Name: Carla Davis
Title: Contracting Officer
Agency: DHS - Office of Procurement Operations
Address: 245 Murray Lane, SW
Mailstop 0115
Washington, DC 20528-0115
Voice: TBD
Email: TBD
G.3. CONTRACTING OFFICER’S AUTHORITY
The Contracting Officer (CO) assigned to this contract has responsibility for ensuring the performance of all necessary actions for effective contracting; ensuring compliance with the terms of the contract and safeguarding the interests of the United States in its contractual relationships.
The Contracting Officer (CO) is the only individual who has the authority to enter into, administer, or terminate this contract and is the only person authorized to approve changes to any of the requirements under this contract, and notwithstanding any provision contained elsewhere in this contract, this authority remains solely with the CO.
It is the Contractor’s responsibility to contact the CO immediately if there is even the appearance of any technical direction that is or may be outside the scope of the contract.
The Government will not reimburse the Contractor for any work not authorized by the CO, including work outside the scope of the contract.
https://www.fbo.gov/index?s=opportunity&mode=form&id=90399125fc575caa7b316dce773b1192&tab=core&_cview=1
Your-Welcome ~ Glad to hear I was-able to help..
As They Say, All For One, and One For All..
Everybody Working Together, To Help Sort Out The Facts, Makes It Easier For Everyone..
Glad to see you're-comprehending the facts, too, besides-me..
Information and Facts Pertaining to PSID
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal, January 25, 2013
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Solicitation Number: HSHQDC-13-R-00026
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)
Download/View HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal, HSHQDC-13-R-00026
Notice Type: Presolicitation
C.1.2. TWO STAGE PROCUREMENT
DHS plans to conduct a two-stage procurement for the Gen-3 Phase II acquisition using a competitive down-selection technique between stages.
Stage 1 will be for Performance Testing of candidate systems and
Stage 2 will be for Operational Test and Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2 after a competive down selection between stages.
At the conclusion of Stage 1 a separate solicitation will be issued for Stage 2 requirements.
Stage 2 will be a full and open competition.
As in Stage 1, Stage 2 offerors must also demonstrate a design maturity equivalent to that of Technology Readiness Level 7, or greater, as described in Section C.2.5. below.
In addition, they must provide an equivalent third-party data set as was generated during Stage 1.
DRAFT Request for Proposal: HSHQDC-13-R-00026
Type: Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date: January 25, 2013
HSHQDC-13-R-00026_COVER_LETTER.pdf (132.85 Kb)
Description: Cover Letter: DRAFT Request for Proposal, HSHQDC-13-R-00026
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)Download/View
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal,
HSHQDC-13-R-00026 J.1_Cost_Pricing_Schedule.xls (35.50 Kb)
Description: ATTACHMENT J.1: Cost/Pricing Schedule
J.6_Question_and_Answer_Sheet.xlsx (11.64 Kb)
Description: ATTACHMENT J.6: Draft RFP Question and Answer Sheet
J.8_NonDisclosure_Agreement.pdf (32.19 Kb)
Description: ATTACHMENT J.8: BioWatch Non-Disclosure Agreement
J.10...Subcontracting_Plan_Checklist.pdf (632.32 Kb)
Description: ATTACHMENT J.10: Small Business Subcontracting Plan Checklist
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
https://www.fbo.gov/index?s=opportunity&mode=form&id=cd3f4aa9250b9d0e77118d4d5693c2a1&tab=core&_cview=0
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
greaseyfingers Tuesday, March 05, 2013 7:06:59 AM
Re: Robsct post# 6487 Post #6489 of 6495
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85286818
Official Information from the Government's Website..
BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Changed
Feb 08, 2013
1:35 pm
Solicitation Number:
HSHQDC-13-R-00026 Notice Type:
Modification/Amendment Synopsis:
Added: Feb 08, 2013 1:35 pm
The purpose of this update is to inform interested parties that posting of the draft RFP does not represent a commitment by the Government to release a final RFP or to award a contract.
The draft RFP is posted for purposes of obtaining industry comments and feedback on the proposed solicitation approach for fulfilling Phase II, Stage 1 requirements.
Award of a Phase II, Stage 1 contract will be subject to the outcome of a Gen-3 Analysis of Alternatives (AoA) initiated by the Department of Homeland Security in July 2012.
A decision on the Gen-3 program is projected in the fall of 2013
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
following completion of the AoA.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Please continue to monitor FedBizOpps for additional updates.
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
United States
Primary Point of Contact.:
Carla Davis,
Contracting Officer
biowatchgen3@hq.dhs.gov
https://www.fbo.gov/index?id=90399125fc575caa7b316dce773b1192
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
greaseyfingers Friday, March 01, 2013 12:20:40 AM
Re: Robsct post# 5998 Post #6052 of 6495
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85150538
That was Then ~ This is Now
Carefully Listen to 12-26-12 SmallCapVoice.com Interview with (PSID), PositiveID Corporation's CEO, William Caragol at, http://smallcapvoice.com/blog/12-26-12-smallcapvoice-interview-with-positiveid-corporation-psid/
Positive ID's, CEO, William Caragol should be more of an expert authority, concerning PSID, than anyone else, including everyone's opinion that's on iHub..IMO
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PositveID's CEO William Caragol clearly says, in his 12-26-12 audio interview, http://smallcapvoice.com/blog/12-26-12-smallcapvoice-interview-with-positiveid-corporation-psid/, that the Request For Proposal vendor, or vendors will be chosen by DHS, to begin their Final Request For Proposal, pilot program's first phase Performance Competition Testing that's going to be announced by the end of the 3rd quarter of 2013, which would be June 30th.
This Final Request For Proposal, pilot program's first phase Competition Testing testing is projected to last throughout the remainder of 2013.
The integration of the BioWatch Generation3 program system is estimated at 3.1 billion dollars, during it's rollout over the next 5 to 6 years.
But, before this can happen, the BioWatch Generation3, Request For Propoal, chosen vendor, or vendors will have to complete the 18 months of Performance, first phase, Competion Testing.
Then, one and only one, of the competing vendors will be chosen for receiving the Final Request For Proposal Contract for the Operational, second phase Testing of the BioWatch Generation3 program.
After the Final Request For Proposal Contract for the Operational, second phase Testing of the BioWatch Generation3 program is completed in 2016.
DHS then may, upon it's discretion, implement and deploy up to 2500 BioWatch Generation Gen3 systems over the next 5 to 6 years.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The Final Request For Proposal for BioWatcj Generation 3 Performance Testing, during Stage 1, is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th.
The Stage 1 contract is expected to have a performance testing period of 18 months.
The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://investors.positiveidcorp.com/releasedetail.cfm?releaseid=738584
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Performance-testing for the current-BioWatch-Gen-3 solicitation is 18 months, during the first stage of the competition.
The procurement for BioWatch Gen-3 Phase II will occur in two stages, DHS said.
The first stage involves performance testing of proposed biodetector systems competing against each other.
The period of performance testing for the current BioWatch Gen-3 solicitation is only 18 months, during the first stage of the competition.
The second phase, of the competition, involves operational testing and evaluation as well as production, deployment, sustainment and disposal.
DHS will only be making final one award for the second-stage of the BioWatch Gen-3 Competitive Down Selection.
Hopefully, PSID will be chosen as the one, and only winner during this Final Request For Proposal Phase of The Competition..
DHS asked interested companies to submit questions on the draft RFP by Feb. 11
Consulting firm Deltek, Herndon, Va., listed BioWatch Gen-3 as the only DHS program in its top 20 federal opportunities for contractors in fiscal year 2013. BioWatch Gen-3 represents a potential $3.1 billion value over five years, according to Deltek's estimates.
The DHS Office of Health Affairs runs the BioWatch program in partnership with the Environmental Protection Agency, the FBI and the Centers for Disease Control and Prevention.
http://www.hstoday.us/focused-topics/information-technology/single-article-page/more-info-on-biowatch-3-revealed-in-draft-solicitation.html
bull_investor Sunday, February 24, 2013 12:06:53 PM
Re: colocowboy post# 5794 Post #5796 of 5917
From the GAO, (Government Accountability Office) documents.
Estimated Schedule for Key Remaining Gen-3 Deployment Steps (as of September 2012):
ADE 2B:
Q4 2013 -to- Q2 2015 -- Laboratory Performance testing
Q4 2015 -to- Q3 2016 -- Operational testing, including IT network.
ADE 3:
Q4 2016 -to- Q1 2022 -- Production of approx. 2500 Gen-3 units and phased deployment to 50 jurisdictions
Q3 2022 -- Full operational capability.
** ADE - Acquisition Decision Event
** Q - Fiscal year quarter
Source: GAO Analysis of BioWatch program documents.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84947393
bull_investor Monday, February 18, 2013 8:30:39 AM
Re: None Post #5347 of 5917
Lets Break Down the Basics (BDB)-
==> Two key terms:
1 - RFP : solicitation through bidding process, here the solicitor knows what he wants, in this RFP, everything is listed, including price, risk factors, what is achievable and what is not. This is step 1 of procurement, a sure deal. according to news release this date could be on or before June 30 2013
2 - DRAFT RFP : is not a formal solicitation tool, rather it is used to gather comments and suggestions from potential offerors. The DRFP is mandatory for all competitive acquisitions expected to exceed $25 million; it is optional for all other acquisitions. It is designed to reduce proposal preparation and evaluation time and promote a clearer understanding to industry of the requirements with a goal of a more effective and less costly contract.
Now note those "two key terms" in the Feb 6, 2013 news release:
http://investors.positiveidcorp.com/releasedetail.cfm?releaseid=738584
Title: PositiveID Reports Issuance of Draft RFP From Dept of Homeland Security for BioWatch Generation 3
PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of biological detection and diagnostics solutions, today announced that the U.S. Department of Homeland Security ("DHS") released a draft request for proposal ("RFP") for Stage 1 of BioWatch Generation 3, an autonomous biodetection system designed to protect the nation against biological threats. The final RFP for Stage 1 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th. The Stage 1 contract is expected to have a performance period of 18 months. The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707176
bull_investor Sunday, February 24, 2013 11:25:42 AM
Re: Robsct post# 5787 Post #5792 of 5917
DHS PDF says:
"The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2
after a competive down selection between stages"
It says one contract for Stage 2 - what does one contract mean??
is it one vendor? or
can a contract be of multiple vendors(PSID & NOC)?
if it is one vendor, then most likely it is PSID,
since CEO was saying that in past press releases!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84946722
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Waiting in-anticipation for PSID to win the BioWatch-Gen3-Contract
August 6, 2012 (Investorideas.com newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a news alert for biodefense stocks.
PositiveID Corporation (OTCBB: PSID) and Northrop Grumman Corporation (NYSE:NOC) as both companies prepare for technology acquisitions and procurement for BioWatch Generation 3 this fall.
In July 2012, Northrop Grumman Corporation (NYSE:NOC) reported that its Next Generation Automated Detection System (NG-ADS) for homeland defense applications has successfully completed a rigorous field test and is ready for the program's next phase.
The NG-ADS technology is a competitor for the Department of Homeland Security's (DHS) upcoming BioWatch Gen-3 Phase II acquisition.
The program seeks to deploy a nationwide network of fully autonomous bio-detectors in major metropolitan areas across the United States to provide early warning of a biological attack. DHS recently announced that a request for proposals will be issued later this year.
The request for proposal got postponed by DHS, as we all know, into 2013.
As a fully automated biological detection system, the NG-ADS continuously collects air samples, analyzes the samples for the presence of multiple biological pathogens, and automatically reports results to public health officials multiple times each day through a secure data network.
More than 20,000 samples were collected and analyzed during the recent field test in a variety of indoor and outdoor locations in a major city in the United States .
"There are concerns that our nation won't be ready to respond should a biological attack occur," said Dave Tilles, director of Homeland Security programs at Northrop Grumman's Electronic Systems sector.
"Early warning provided by an automated detection system such as the NG-ADS will allow the nation's public health and public safety officials to proactively manage the response to a biological event to reduce exposure and treat the affected population to minimize casualties."
Since the successful field test, additional improvements have been made to the NG-ADS to enhance the system's performance while reducing its life-cycle cost.
The proven, life-saving capability of the NG-ADS draws upon Northrop Grumman's decade long experience developing, testing, deploying, and operating bio-detection systems for the U.S. government and other customers.
PositiveID Corporation (OTCBB: PSID) recently reported it added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems ("MFS") subsidiary. The Company will utilize Dr. Smith's expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security ("DHS") for BioWatch Generation 3, a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America 's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. www.PositiveIDCorp.com.
http://www.investorideas.com/news/2012/main/08062.asp
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
greaseyfingers Friday, March 01, 2013 1:24:03 AM
Re: Robsct post# 5388 Post #6053 of 6495
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85151869
Getting the facts straight ~ regarding PSID..
It appears you have good intentions ~ but most seem to be questioning your opinion ~ even the website links you're providing are in contradiction of the actual facts concerning PSID..
The information you're website link is referring to, is from (June 2007)
The program was kicked off in 2007 and said to be scheduled for testing in 2008 with completion of the whole program between 2009 and 2012.
It Says, "BioWatch 3 is expected to be pilot tested in fiscal year 2008 and fully deployed between fiscal years 2009 and 2012."
http://www.dhs.gov/lab-box
However, this official time frame testing never happened, during the lime line, as was first projected by the government's DHS.
The government's Department of Homeland Security kept postponing it, from occurring, each and every year, until allowing their Final Draft Request For Proposal Competition Testing, for Stage 1 Performance Testing, and Stage 2 Operational Testing, to start proceeding forward, as the first stage is doing, now.
makingbiigdough Monday, February 18, 2013 11:08:02 AM
Re: Robsct post# 5351 Post #5368 of 5378
Rob you are right BUT also wrong! This is a WHOLE NEW PROCUREMENT! Yes you are correct we are in Phase II, however we are at stage I. My wife suggest we ALL need to talk less and read MORE! Lol
The GREAT News is that we are VERY close to the DHS releasing of the FINAL RFP!! I beleieve that by the 2nd week of March at the latest! Could happen MUCH sooner guys! JMO
After RFP is released than we can expect a contract award being issued for multiple contracts for a firm fixed amount, as well as cost re-imbursement! This should imo happen within 2-4wks after RFP!
Also there just might not be an industry day, if so it will be just a formality, just as with the DRFP! Will NOT have any significance at all per my wife! She was confident in saying that RFP could be released at anytime! Gotta run guys hope this helps! Don't STRESS remain PATIENT we are VERY close my friends!
My wife from her experience working for DoD for MANY years says with the UPMOST CONFIDENCE that PSID hands down will be chosen for 1 of the multiple contract awards being awarded in STAGE I!
Her final conclusion is that PSID like Coca Cola is a stock you don't eat on or have to pay your rent with! What she means is IT is going to happen, but be able to pay your bills in the meantime! Remember it is a LONG GREVIOUS process anytime you are dealing with our GOV!!
I once again think it is sooner than later! Gotta run take care everyone! MBD
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84709677
Davecatchndawave Monday, February 18, 2013 9:08:10 AM
Re: A deleted message Post #5352 of 5374
I want to believe this. I am having trouble with the fact that Caragol's PR doesn't jive with you. Can you explain the psid PR?
psid PR feb 6
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707630
bull_investor Monday, February 18, 2013 11:40:18 AM
Re: makingbiigdough post# 5368 Post #5379 of 5388
Rob-
IMO,focus on getting your post correct before calling others misleading.
No offence meant! back to relax mode.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84710325
ayuncle Monday, February 18, 2013 8:43:26 AM
Re: Robsct post# 5336 Post #5349 of 5400
I think the last post by Bull Investor clears it up accurately in stating that we are still in that 18 month waiting game which will begin after June 30th.
I read both links again and came to that same conclusion.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707319
greaseyfingers Sunday, February 17, 2013 10:23:37 PM
Re: None Post #5335 of 5400
Performance-testing for the current-BioWatch-Gen-3 solicitation is 18 months, during the first stage of the competition.
The procurement for BioWatch Gen-3 Phase II will occur in two stages, DHS said.
The first stage involves performance testing of proposed biodetector systems competing against each other.
The period of performance testing for the current BioWatch Gen-3 solicitation is only 18 months, during the first stage of the competition.
The second phase, of the competition, involves operational testing and evaluation as well as production, deployment, sustainment and disposal.
DHS will only be making final one award for the second-stage of the BioWatch Gen-3 Competitive Down Selection.
Hopefully, PSID will be chosen as the one, and only winner during this Final Request For Proposal Phase of The Competition..
DHS asked interested companies to submit questions on the draft RFP by Feb. 11
Consulting firm Deltek, Herndon, Va., listed BioWatch Gen-3 as the only DHS program in its top 20 federal opportunities for contractors in fiscal year 2013. BioWatch Gen-3 represents a potential $3.1 billion value over five years, according to Deltek's estimates.
The DHS Office of Health Affairs runs the BioWatch program in partnership with the Environmental Protection Agency, the FBI and the Centers for Disease Control and Prevention.
http://www.hstoday.us/focused-topics/information-technology/single-article-page/more-info-on-biowatch-3-revealed-in-draft-solicitation.html
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PositiveID has clearly stated the specific timeline information for the BioWatch Generation 3, stage 1 performance testing phase, in their February 6, 2013 PositiveID Reports Issuance of Draft RFP From Dept of Homeland Security for BioWatch Generation 3, if you read it very closely.
It Specifically Says,
"The final RFP for Stage 1 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th."
"The Stage 1 contract is expected to have a performance period of 18 months. The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years."
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~Information which was published by PositveID for investors and to whom it may concern.
Clearly indicates and specifys that the BioWatch Generation 3 final Request For Proposal for stage 1 performance testing phase is going to be released, sometime, in the government's third quarter of fiscal 2013, which ends June 30th.
Once that event takes place, as they clearly specify.
Then, The Stage 1 contract is expected to have a performance period of 18 months.
http://investors.positiveidcorp.com/releasedetail.cfm?ReleaseID=738584
Official Information from the Government's Website..
BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Changed
Feb 08, 2013
1:35 pm
Solicitation Number:
HSHQDC-13-R-00026 Notice Type:
Modification/Amendment Synopsis:
Added: Feb 08, 2013 1:35 pm
The purpose of this update is to inform interested parties that posting of the draft RFP does not represent a commitment by the Government to release a final RFP or to award a contract.
The draft RFP is posted for purposes of obtaining industry comments and feedback on the proposed solicitation approach for fulfilling Phase II, Stage 1 requirements.
Award of a Phase II, Stage 1 contract will be subject to the outcome of a Gen-3 Analysis of Alternatives (AoA) initiated by the Department of Homeland Security in July 2012.
A decision on the Gen-3 program is projected in the fall of 2013
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
following completion of the AoA.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Please continue to monitor FedBizOpps for additional updates.
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
United States
Primary Point of Contact.:
Carla Davis,
Contracting Officer
biowatchgen3@hq.dhs.gov
https://www.fbo.gov/index?id=90399125fc575caa7b316dce773b1192
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
BioWatch Gen-3 Phase II, Stage1 Presolicitation and Draft Request for Proposal
Solicitation Number: HSHQDC-13-R-00026
Agency: Department of Homeland Security
Office: Office of the Chief Procurement Officer
Location: Office of Procurement Operations
Solicitation Number: HSHQDC-13-R-00026
Notice Type: Presolicitation
C.1.2. TWO STAGE PROCUREMENT
DHS plans to conduct a two-stage procurement for the Gen-3 Phase II acquisition using a competitive down-selection technique between stages.
Stage 1 will be for Performance Testing of candidate systems and Stage 2 will be for Operational Test and Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2 after a competive down selection between stages.
At the conclusion of Stage 1 a separate solicitation will be issued for Stage 2 requirements.
Stage 2 will be a full and open competition.
As in Stage 1, Stage 2 offerors must also demonstrate a design maturity equivalent to that of Technology Readiness Level 7, or greater, as described in Section C.2.5. below.
In addition, they must provide an equivalent third-party data set as was generated during Stage 1.
DRAFT Request for Proposal: HSHQDC-13-R-00026
Type: Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date: January 25, 2013
HSHQDC-13-R-00026_COVER_LETTER.pdf (132.85 Kb)
Description: Cover Letter: DRAFT Request for Proposal, HSHQDC-13-R-00026
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen-3_Phase_2_... (588.76 Kb)Download/View
HSHQDC-13-R-00026_DRAFT_RFP,_BioWatch_Gen3_Phase_2_Stage_1.pdfDescription: DRAFT Request for Proposal,
HSHQDC-13-R-00026 J.1_Cost_Pricing_Schedule.xls (35.50 Kb)
Description: ATTACHMENT J.1: Cost/Pricing Schedule
J.6_Question_and_Answer_Sheet.xlsx (11.64 Kb)
Description: ATTACHMENT J.6: Draft RFP Question and Answer Sheet
J.8_NonDisclosure_Agreement.pdf (32.19 Kb)
Description: ATTACHMENT J.8: BioWatch Non-Disclosure Agreement
J.10...Subcontracting_Plan_Checklist.pdf (632.32 Kb)
Description: ATTACHMENT J.10: Small Business Subcontracting Plan Checklist
Contracting Office Address:
Office of the Chief Procurement Officer
Washington, District of Columbia 20528
United States
Place of Performance:
Continental United States
https://www.fbo.gov/index?s=opportunity&mode=form&id=cd3f4aa9250b9d0e77118d4d5693c2a1&tab=core&_cview=0
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Robsct Tuesday, March 05, 2013 5:19:45 AM
Re: None Post #6487 of 6488
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85285694
I'll post this again. According to DHS's timetable they want to award the big contract to produce and deploy Gen-3 this year.
The program was kicked off in 2007 and said to be scheduled for testing in 2008 with completion of the whole program in 2012. The article identifies the division of DHS as the same one that Caragol stated in the recent PR. It's the same testing phase...and it's now done.
"This is the two-pronged goal of research behind the Generation 3 BioWatch Program, which is funded by the Chemical and Biological Division at the Department of Homeland Security's (DHS) Science and Technology Directorate (S&T). "
http://www.dhs.gov/lab-box
"William J. Caragol, Chairman and CEO of PositiveID, stated, "We believe that PositiveID is well positioned for BioWatch Generation 3, as our M-BAND detection technology (Microfluidics-based BioAgent Autonomous Networked Detector) was the only system of its kind successfully demonstrated in the field as part of the DHS Science & Technology Directorate ("S&T") BAND (BioAgent Autonomous Networked Detector) Program. In October 2012, we issued a corporate update to our stockholders about the BioWatch program, stating that we were in discussions with strategic partners to manufacture and sell M-BAND, and reiterating our belief that the BioWatch program would soon begin to roll out."
http://finance.yahoo.com/news/positiveid-reports-issuance-draft-rfp-213000044.html
you posted, "Successfully completed Phase I Characterization Testing and the Field Test in a current BioWatch jurisdiction," ~ which appears to be in a different category of testing than The DHS BioWatch Gen-3 Stage 1, Performance Testing for the OFFICIAL COMPETITION CONTEST..
On 02/06/2013 - The U.S. Department of Homeland Security ("DHS") released a draft request for proposal ("RFP") for Stage 1, Performance Testing of BioWatch Generation 3, an autonomous biodetection system designed to protect the nation against biological threats..
The final RFP for Stage 1, Performance Testing is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th.
The Stage 1, Performance Testing Contract is expected to have a performance period of 18 months.
The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://ih.advfn.com/p.php?pid=nmona&article=56177810
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Robsct Friday, March 01, 2013 9:06:33 AM
Re: None Post #6056 of 6388
For anyone who missed it DHS stated in their current budget that the Phase I testing has been successfully completed. I think that since DHS did the testing that they would know what they are talking about. It's on page 139.
BioWatch Gen-3
•
Successfully completed Phase I Characterization Testing and the Field Test in a current BioWatch jurisdiction.
Subsystem and system characterization testing demonstrated pre-production system(s) under test against Gen-3 operational requirements.
The Field Test demonstrated the operational capability of the autonomous biodetection system under test against the Gen-3 operational requirements.
The Phase I testing results will support the Department’s decision to proceed to Phase I, Production,and Deployment.
http://www.dhs.gov/xlibrary/assets/mgmt/dhs-budget-in-brief-fy2013.pdf
PSID's-management has always been a cash-burner money pit..
PSID's management is responsible for letting a $9.00 stock go all the way down to 2 cents, reflecting it's current value, by lacking to earn any income revenue off any of their many products being developed and promoted..
PSID's top management has always paid themselves outrageous salaries, bonuses, and rewarded themselves with many millions of stock shares..
There are 475 million authorized shares of PSID stock, of which 244 million shares are outstancing..
PSID management knows they can't keep diluting a nearly rock bottomed, 2 cent stock without making it look to obvious to everyone..
PSID likes to go through money, like it's going out of style toilet paper..
What better way to do this, than do a reverse stock split, that will raise the price proportionately to the split ratio..
Then PSID's management can raise more money, for themselves, by selling more shares and keep diluting that money, too, until it's nearly gone, and back at the 2 cent level, again..
If PSID's BioWatch Generation-3, M-Band, receives the DHS Contract and starts earning revenue income, as I hope happens..
Then PSID won't have to resort to their diluting tactics and eroding share holder's value..
PSID's, (SHADY), Rationale for Doing a Reverse Stock-Split..IMO
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
LET'S ALL US uPSIDe LONG TERM INVESTORS HOPE FOR THE BEST, and EXPECT THE WORST NOT TO HAPPEN..
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
If PSID does a dreaded reverse stock split in the ratio of 1-for-10 to 1-for-25, as determined by the Board of Directors..
It seems to me, doing that would make it much easier for PSID Management to create more Dilution, by greatly reducing PSID stock shares, then the remaining shares would be higher priced..
Then, PSID could fly under the radar much easier, creating less suspicion, and increase the amount of authorized shares to be sold by PSID Management, for increasing their GREEDY SALARIES and BONUSES, and cause more DILUTION to PSID Share Holder Value..
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The Board of Directors believes that it is in the best interests of the Company and its stockholders to reduce the number of issued and outstanding shares through a reverse stock split. Immediately following the completion of the reverse stock split, the number of shares of PositiveID common stock issued and outstanding or held in treasury will be reduced proportionately based on the reverse stock split ratio of 1-for-10 to 1-for-25, as determined by the Board of Directors.
A reverse stock split by a publicly traded company reduces the number of shares outstanding, but leaves the market capitalization of the company the same, which results in an increase in the price per share of the company’s stock. Put another way, after a reverse stock split, the enterprise value of the company is spread over fewer shares and so the per share price of the stock will be higher.
The Board of Directors believes implementing a reverse stock split is likely to increase the market price for PositiveID common stock as fewer shares will be outstanding. The Board of Directors further believes that the increased market price of PositiveID common stock expected as a result of implementing the reverse stock split may improve marketability and liquidity of PositiveID common stock and encourage interest and trading in PositiveID common stock.
We are asking stockholders to approve this Proposal because we believe a reverse stock split will result in a higher price per share for outstanding shares of our common stock. This, we believe, could provide a number of potential advantages.
(BULL CRAP) Potential Advantages from a Reverse Stock Split
We believe that the reverse stock split could enhance the appeal of our common stock to the financial community, including institutional investors, and the general investing public. We believe that a number of institutional investors and investment funds are reluctant to invest in lower priced securities and that brokerage firms may be reluctant to recommend lower priced stock to their clients, which may be due in part to a perception that lower-priced securities are less promising as investments, are less liquid in the event that an investor wishes to sell his, her or its shares, or are less likely to be followed by institutional securities research firms. We believe that the reduction in the number of issued and outstanding shares of our common stock caused by the reverse stock split, together with the anticipated increased stock price immediately following and resulting from the reverse stock split, may encourage further interest and trading in our common stock and thus possibly promote greater liquidity for our stockholders, thereby resulting in a broader market for our common stock than that which currently exists.
Certain Risks Associated with the Reverse Stock Split
There can be no assurance that the total market capitalization of our common stock (the aggregate value of all PositiveID common stock at the then market price) after the implementation of a reverse stock split will be equal to or greater than the total market capitalization before a reverse stock split or that the per share market price of our common stock following a reverse stock split will increase in proportion to the reduction in the number of shares of our common stock outstanding before the reverse stock split.
There can be no assurance that the market price per new share of our common stock after a reverse stock split will remain unchanged or increase in proportion to the reduction in the number of old shares of our common stock outstanding before a reverse stock split. For example, based on the closing price of our common stock on February 28, 2013 of $0.02 per share, if the Board of Directors were to implement the reverse stock split and utilize a ratio of 1-for-10, we cannot assure you that the post-split market price of our common stock would be $0.20 (that is, $0.02 × 10) per share or greater. In many cases, the market price of a company’s shares declines after a reverse stock split.
Accordingly, the total market capitalization of our common stock after a reverse stock split when and if implemented may be lower than the total market capitalization before the reverse stock split. Moreover, in the future, the market price of our common stock following a reverse stock split may not exceed or remain higher than the market price prior to the reverse stock split.
The proposed reverse stock split may decrease the liquidity of our stock.
The liquidity of our capital stock may be harmed by the proposed reverse split given the reduced number of shares that will be outstanding after the reverse stock split, particularly if the stock price does not increase as a result of the reverse stock split. In addition, the proposed reverse stock split may increase the number of stockholders who own odd lots (less than 100 shares) of our common stock, creating the potential for such stockholders to experience an increase in the cost of selling their shares and greater difficulty effecting sales.
If we effect a reverse stock split, the resulting per-share stock price may not attract institutional investors or investment funds and may not satisfy the investing guidelines of such investors and, consequently, the trading liquidity of our common stock may not improve.
While our Board of Directors believes that a higher stock price may help generate greater/broader investor interest, there can be no assurance that a reverse stock split will result in a per-share price that will attract institutional investors or investment funds or that such share price will satisfy the investing guidelines of institutional investors or investment funds. As a result, the trading liquidity of our common stock may not necessarily improve.
http://www.sec.gov/Archives/edgar/data/1347022/000139843213000124/i12116.htm
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
sayuncle Friday, March 01, 2013 5:52:35 PM
Re: condoe3 post# 6083 Post #6085 of 6100
Can we get some DD on this ASAP? There is no date on it but it has Positive ID and Bill Caragol's name all over it. Something may be off with this one.
I noticed that stock prices dived under 2 cents. Hmm, something is wrong with this picture.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85190843
Robsct Friday, March 01, 2013 6:24:19 PM
Re: Pisd post# 6092 Post #6102 of 6107
Well obviously the only reason to reverse split is to get a share price high enough to get back on the nasdaq and open it up to the big money investors before the contract is awarded to us. That would give PSID a bigger run up when it happens. Ordinarily a r/s would be the end of the stock on the BB but if we get on the nasdaq and then get the contract we could be just fine. They have obviously thought this out carefully and have a plan.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85191427
Robsct Friday, March 01, 2013 6:36:12 PM
Re: None Post #6103 of 6108
No, it won't work. Even a 1 for 25 split would only give us a .50 cents a share pps and that's not high enough to get back on the nasdaq. And that's at today's price before a sell off. There are not enough shares involved and the price is too low. There's got to be another reason. What if they knew a filing like this would cause a sell off that would free up many millions of shares for someone to gobble up? And they have no intention of doing a R/S.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85191619
Looking-at the PSID uPSIDe ~ Patience is a Virtue..
They say, "Patience is a Virtue, and All good things come to those who Wait"
I hope that saying holds true for all us long term PSID share holders, who are cautiously optimistic about the future of this Company being able to generate successful revenue earnings from their products, someday, within a reasonable period of time..
Getting the facts straight ~ regarding PSID..
It appears you have good intentions ~ but most seem to be questioning your opinion ~ even your own website links seem to be in contradiction of the actual facts concerning PSID..
The information you're website link is referring to, is from (June 2007) The program was kicked off in 2007 and said to be scheduled for testing in 2008 with completion of the whole program between 2009 and 2012.
It Says, "BioWatch 3 is expected to be pilot tested in fiscal year 2008 and fully deployed between fiscal years 2009 and 2012."
http://www.dhs.gov/lab-box
However, this official time frame testing never happened, during the lime line, as was first projected by the government's DHS.
The government's Department of Homeland Security kept postponing it, from occurring, each and every year, until allowing their Final Draft Request For Proposal Competition Testing, for Stage 1 Performance Testing, and Stage 2 Operational Testing, to start proceeding forward, as the first stage is doing, now.
makingbiigdough Monday, February 18, 2013 11:08:02 AM
Re: Robsct post# 5351 Post #5368 of 5378
Rob you are right BUT also wrong! This is a WHOLE NEW PROCUREMENT! Yes you are correct we are in Phase II, however we are at stage I. My wife suggest we ALL need to talk less and read MORE! Lol
The GREAT News is that we are VERY close to the DHS releasing of the FINAL RFP!! I beleieve that by the 2nd week of March at the latest! Could happen MUCH sooner guys! JMO
After RFP is released than we can expect a contract award being issued for multiple contracts for a firm fixed amount, as well as cost re-imbursement! This should imo happen within 2-4wks after RFP!
Also there just might not be an industry day, if so it will be just a formality, just as with the DRFP! Will NOT have any significance at all per my wife! She was confident in saying that RFP could be released at anytime! Gotta run guys hope this helps! Don't STRESS remain PATIENT we are VERY close my friends!
My wife from her experience working for DoD for MANY years says with the UPMOST CONFIDENCE that PSID hands down will be chosen for 1 of the multiple contract awards being awarded in STAGE I!
Her final conclusion is that PSID like Coca Cola is a stock you don't eat on or have to pay your rent with! What she means is IT is going to happen, but be able to pay your bills in the meantime! Remember it is a LONG GREVIOUS process anytime you are dealing with our GOV!!
I once again think it is sooner than later! Gotta run take care everyone! MBD
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84709677
Davecatchndawave Monday, February 18, 2013 9:08:10 AM
Re: A deleted message Post #5352 of 5374
I want to believe this. I am having trouble with the fact that Caragol's PR doesn't jive with you. Can you explain the psid PR?
psid PR feb 6
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707630
bull_investor Monday, February 18, 2013 11:40:18 AM
Re: makingbiigdough post# 5368 Post #5379 of 5388
Rob-
IMO,focus on getting your post correct before calling others misleading.
No offence meant! back to relax mode.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84710325
ayuncle Monday, February 18, 2013 8:43:26 AM
Re: Robsct post# 5336 Post #5349 of 5400
I think the last post by Bull Investor clears it up accurately in stating that we are still in that 18 month waiting game which will begin after June 30th.
I read both links again and came to that same conclusion.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707319
greaseyfingers Sunday, February 17, 2013 10:23:37 PM
Re: None Post #5335 of 5400
Performance-testing for the current-BioWatch-Gen-3 solicitation is 18 months, during the first stage of the competition.
The procurement for BioWatch Gen-3 Phase II will occur in two stages, DHS said.
The first stage involves performance testing of proposed biodetector systems competing against each other.
The period of performance testing for the current BioWatch Gen-3 solicitation is only 18 months, during the first stage of the competition.
The second phase, of the competition, involves operational testing and evaluation as well as production, deployment, sustainment and disposal.
DHS will only be making final one award for the second-stage of the BioWatch Gen-3 Competitive Down Selection.
Hopefully, PSID will be chosen as the one, and only winner during this Final Request For Proposal Phase of The Competition..
DHS asked interested companies to submit questions on the draft RFP by Feb. 11
Consulting firm Deltek, Herndon, Va., listed BioWatch Gen-3 as the only DHS program in its top 20 federal opportunities for contractors in fiscal year 2013. BioWatch Gen-3 represents a potential $3.1 billion value over five years, according to Deltek's estimates.
The DHS Office of Health Affairs runs the BioWatch program in partnership with the Environmental Protection Agency, the FBI and the Centers for Disease Control and Prevention.
http://www.hstoday.us/focused-topics/information-technology/single-article-page/more-info-on-biowatch-3-revealed-in-draft-solicitation.html
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PositiveID has clearly stated the specific timeline information for the BioWatch Generation 3, stage 1 performance testing phase, in their February 6, 2013 PositiveID Reports Issuance of Draft RFP From Dept of Homeland Security for BioWatch Generation 3, if you read it very closely.
It Specifically Says,
"The final RFP for Stage 1 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th."
"The Stage 1 contract is expected to have a performance period of 18 months. The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years."
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~Information which was published by PositveID for investors and to whom it may concern.
Clearly indicates and specifys that the BioWatch Generation 3 final Request For Proposal for stage 1 performance testing phase is going to be released, sometime, in the government's third quarter of fiscal 2013, which ends June 30th.
Once that event takes place, as they clearly specify.
Then, The Stage 1 contract is expected to have a performance period of 18 months.
http://investors.positiveidcorp.com/releasedetail.cfm?ReleaseID=738584
That was Then ~ This is Now
Listen to 12-26-12 SmallCapVoice Interview with PositiveID Corporation (PSID) at, http://smallcapvoice.com/blog/12-26-12-smallcapvoice-interview-with-positiveid-corporation-psid/
Positive ID's, CEO, William Caragol should be more of an authority, concerning PSID, more so, than anyone else, including everyone's opinion that's on iHub..IMO
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PositveID's CEO William Caragol clearly says, in his 12-26-12 audio interview, http://smallcapvoice.com/blog/12-26-12-smallcapvoice-interview-with-positiveid-corporation-psid/, that the Request For Proposal vendor, or vendors will be chosen by DHS, to begin their Final Request For Proposal, pilot program's first phase Performance Competition Testing that's going to be announced by the end of the 3rd quarter of 2013, which would be June 30th.
This Final Request For Proposal, pilot program's first phase Competition Testing testing is projected to last throughout the remainder of 2013.
The integration of the BioWatch Generation3 program system is estimated at 3.1 billion dollars, during it's rollout over the next 5 to 6 years.
But, before this can happen, the BioWatch Generation3, Request For Propoal, chosen vendor, or vendors will have to complete the 18 months of Performance, first phase, Competion Testing.
Then, one and only one, of the competing vendors will be chosen for receiving the Final Request For Proposal Contract for the Operational, second phase Testing of the BioWatch Generation3 program.
After the Final Request For Proposal Contract for the Operational, second phase Testing of the BioWatch Generation3 program is completed in 2016.
DHS then may, upon it's discretion, implement and deploy up to 2500 BioWatch Generation Gen3 systems over the next 5 to 6 years.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The Final Request For Proposal for BioWatcj Generation 3 Performance Testing, during Stage 1, is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th.
The Stage 1 contract is expected to have a performance testing period of 18 months.
The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://investors.positiveidcorp.com/releasedetail.cfm?releaseid=738584
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Performance-testing for the current-BioWatch-Gen-3 solicitation is 18 months, during the first stage of the competition.
The procurement for BioWatch Gen-3 Phase II will occur in two stages, DHS said.
The first stage involves performance testing of proposed biodetector systems competing against each other.
The period of performance testing for the current BioWatch Gen-3 solicitation is only 18 months, during the first stage of the competition.
The second phase, of the competition, involves operational testing and evaluation as well as production, deployment, sustainment and disposal.
DHS will only be making final one award for the second-stage of the BioWatch Gen-3 Competitive Down Selection.
Hopefully, PSID will be chosen as the one, and only winner during this Final Request For Proposal Phase of The Competition..
DHS asked interested companies to submit questions on the draft RFP by Feb. 11
Consulting firm Deltek, Herndon, Va., listed BioWatch Gen-3 as the only DHS program in its top 20 federal opportunities for contractors in fiscal year 2013. BioWatch Gen-3 represents a potential $3.1 billion value over five years, according to Deltek's estimates.
The DHS Office of Health Affairs runs the BioWatch program in partnership with the Environmental Protection Agency, the FBI and the Centers for Disease Control and Prevention.
http://www.hstoday.us/focused-topics/information-technology/single-article-page/more-info-on-biowatch-3-revealed-in-draft-solicitation.html
bull_investor Sunday, February 24, 2013 12:06:53 PM
Re: colocowboy post# 5794 Post #5796 of 5917
From the Governtment Accountability Office documents.
Estimated Schedule for Key Remaining Gen-3 Deployment Steps (as of September 2012):
ADE 2B:
Q4 2013 -to- Q2 2015 -- Laboratory Performance testing
Q4 2015 -to- Q3 2016 -- Operational testing, including IT network.
ADE 3:
Q4 2016 -to- Q1 2022 -- Production of approx. 2500 Gen-3 units and phased deployment to 50 jurisdictions
Q3 2022 -- Full operational capability.
** ADE - Acquisition Decision Event
** Q - Fiscal year quarter
Source: GAO Analysis of BioWatch program documents.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84947393
bull_investor Monday, February 18, 2013 8:30:39 AM
Re: None Post #5347 of 5917
Lets Break Down the Basics (BDB)-
==> Two key terms:
1 - RFP : solicitation through bidding process, here the solicitor knows what he wants, in this RFP, everything is listed, including price, risk factors, what is achievable and what is not. This is step 1 of procurement, a sure deal. according to news release this date could be on or before June 30 2013
2 - DRAFT RFP : is not a formal solicitation tool, rather it is used to gather comments and suggestions from potential offerors. The DRFP is mandatory for all competitive acquisitions expected to exceed $25 million; it is optional for all other acquisitions. It is designed to reduce proposal preparation and evaluation time and promote a clearer understanding to industry of the requirements with a goal of a more effective and less costly contract.
Now note those "two key terms" in the Feb 6, 2013 news release:
http://investors.positiveidcorp.com/releasedetail.cfm?releaseid=738584
Title: PositiveID Reports Issuance of Draft RFP From Dept of Homeland Security for BioWatch Generation 3
PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of biological detection and diagnostics solutions, today announced that the U.S. Department of Homeland Security ("DHS") released a draft request for proposal ("RFP") for Stage 1 of BioWatch Generation 3, an autonomous biodetection system designed to protect the nation against biological threats. The final RFP for Stage 1 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th. The Stage 1 contract is expected to have a performance period of 18 months. The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707176
bull_investor Sunday, February 24, 2013 11:25:42 AM
Re: Robsct post# 5787 Post #5792 of 5917
DHS PDF says:
"The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2
after a competive down selection between stages"
It says one contract for Stage 2 - what does one contract mean??
is it one vendor? or
can a contract be of multiple vendors(PSID & NOC)?
if it is one vendor, then most likely it is PSID,
since CEO was saying that in past press releases!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84946722
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Waiting in-anticipation for PSID to win the BioWatch-Gen3-Contract
August 6, 2012 (Investorideas.com newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a news alert for biodefense stocks.
PositiveID Corporation (OTCBB: PSID) and Northrop Grumman Corporation (NYSE:NOC) as both companies prepare for technology acquisitions and procurement for BioWatch Generation 3 this fall.
In July 2012, Northrop Grumman Corporation (NYSE:NOC) reported that its Next Generation Automated Detection System (NG-ADS) for homeland defense applications has successfully completed a rigorous field test and is ready for the program's next phase.
The NG-ADS technology is a competitor for the Department of Homeland Security's (DHS) upcoming BioWatch Gen-3 Phase II acquisition.
The program seeks to deploy a nationwide network of fully autonomous bio-detectors in major metropolitan areas across the United States to provide early warning of a biological attack. DHS recently announced that a request for proposals will be issued later this year.
The request for proposal got postponed by DHS, as we all know, into 2013.
As a fully automated biological detection system, the NG-ADS continuously collects air samples, analyzes the samples for the presence of multiple biological pathogens, and automatically reports results to public health officials multiple times each day through a secure data network.
More than 20,000 samples were collected and analyzed during the recent field test in a variety of indoor and outdoor locations in a major city in the United States .
"There are concerns that our nation won't be ready to respond should a biological attack occur," said Dave Tilles, director of Homeland Security programs at Northrop Grumman's Electronic Systems sector.
"Early warning provided by an automated detection system such as the NG-ADS will allow the nation's public health and public safety officials to proactively manage the response to a biological event to reduce exposure and treat the affected population to minimize casualties."
Since the successful field test, additional improvements have been made to the NG-ADS to enhance the system's performance while reducing its life-cycle cost.
The proven, life-saving capability of the NG-ADS draws upon Northrop Grumman's decade long experience developing, testing, deploying, and operating bio-detection systems for the U.S. government and other customers.
PositiveID Corporation (OTCBB: PSID) recently reported it added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems ("MFS") subsidiary. The Company will utilize Dr. Smith's expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security ("DHS") for BioWatch Generation 3, a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America 's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. www.PositiveIDCorp.com.
http://www.investorideas.com/news/2012/main/08062.asp
I'm expecting PSID to win the Contract, Aren't-you..
The Final Request For Proposal for BioWatcj Generation 3 Performance Testing, during Stage 1, is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th.
The Stage 1 contract is expected to have a performance testing period of 18 months.
The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://investors.positiveidcorp.com/releasedetail.cfm?releaseid=738584
Performance-testing for the current-BioWatch-Gen-3 solicitation is 18 months, during the first stage of the competition.
The procurement for BioWatch Gen-3 Phase II will occur in two stages, DHS said.
The first stage involves performance testing of proposed biodetector systems competing against each other.
The period of performance testing for the current BioWatch Gen-3 solicitation is only 18 months, during the first stage of the competition.
The second phase, of the competition, involves operational testing and evaluation as well as production, deployment, sustainment and disposal.
DHS will only be making final one award for the second-stage of the BioWatch Gen-3 Competitive Down Selection.
Hopefully, PSID will be chosen as the one, and only winner during this Final Request For Proposal Phase of The Competition..
DHS asked interested companies to submit questions on the draft RFP by Feb. 11
Consulting firm Deltek, Herndon, Va., listed BioWatch Gen-3 as the only DHS program in its top 20 federal opportunities for contractors in fiscal year 2013. BioWatch Gen-3 represents a potential $3.1 billion value over five years, according to Deltek's estimates.
The DHS Office of Health Affairs runs the BioWatch program in partnership with the Environmental Protection Agency, the FBI and the Centers for Disease Control and Prevention.
http://www.hstoday.us/focused-topics/information-technology/single-article-page/more-info-on-biowatch-3-revealed-in-draft-solicitation.html
bull_investor Sunday, February 24, 2013 12:06:53 PM
Re: colocowboy post# 5794 Post #5796 of 5917
From GAO documents.
Estimated Schedule for Key Remaining Gen-3 Deployment Steps (as of September 2012):
ADE 2B:
Q4 2013 -to- Q2 2015 -- Laboratory Performance testing
Q4 2015 -to- Q3 2016 -- Operational testing, including IT network.
ADE 3:
Q4 2016 -to- Q1 2022 -- Production of approx. 2500 Gen-3 units and phased deployment to 50 jurisdictions
Q3 2022 -- Full operational capability.
** ADE - Acquisition Decision Event
** Q - Fiscal year quarter
Source: GAO Analysis of BioWatch program documents.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84947393
bull_investor Monday, February 18, 2013 8:30:39 AM
Re: None Post #5347 of 5917
Lets Break Down the Basics (BDB)-
==> Two key terms:
1 - RFP : solicitation through bidding process, here the solicitor knows what he wants, in this RFP, everything is listed, including price, risk factors, what is achievable and what is not. This is step 1 of procurement, a sure deal. according to news release this date could be on or before June 30 2013
2 - DRAFT RFP : is not a formal solicitation tool, rather it is used to gather comments and suggestions from potential offerors. The DRFP is mandatory for all competitive acquisitions expected to exceed $25 million; it is optional for all other acquisitions. It is designed to reduce proposal preparation and evaluation time and promote a clearer understanding to industry of the requirements with a goal of a more effective and less costly contract.
Now note those "two key terms" in the Feb 6, 2013 news release:
http://investors.positiveidcorp.com/releasedetail.cfm?releaseid=738584
Title: PositiveID Reports Issuance of Draft RFP From Dept of Homeland Security for BioWatch Generation 3
PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of biological detection and diagnostics solutions, today announced that the U.S. Department of Homeland Security ("DHS") released a draft request for proposal ("RFP") for Stage 1 of BioWatch Generation 3, an autonomous biodetection system designed to protect the nation against biological threats. The final RFP for Stage 1 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th. The Stage 1 contract is expected to have a performance period of 18 months. The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707176
bull_investor Sunday, February 24, 2013 11:25:42 AM
Re: Robsct post# 5787 Post #5792 of 5917
DHS PDF says:
"The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2
after a competive down selection between stages"
It says one contract for Stage 2 - what does one contract mean??
is it one vendor? or
can a contract be of multiple vendors(PSID & NOC)?
if it is one vendor, then most likely it is PSID,
since CEO was saying that in past press releases!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84946722
Waiting in-anticipation for PSID to win the BioWatch-Gen3-Contract
August 6, 2012 (Investorideas.com newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a news alert for biodefense stocks.
PositiveID Corporation (OTCBB: PSID) and Northrop Grumman Corporation (NYSE:NOC) as both companies prepare for technology acquisitions and procurement for BioWatch Generation 3 this fall.
In July 2012, Northrop Grumman Corporation (NYSE:NOC) reported that its Next Generation Automated Detection System (NG-ADS) for homeland defense applications has successfully completed a rigorous field test and is ready for the program's next phase.
The NG-ADS technology is a competitor for the Department of Homeland Security's (DHS) upcoming BioWatch Gen-3 Phase II acquisition.
The program seeks to deploy a nationwide network of fully autonomous bio-detectors in major metropolitan areas across the United States to provide early warning of a biological attack. DHS recently announced that a request for proposals will be issued later this year.
The request for proposal got postponed by DHS, as we all know, into 2013.
As a fully automated biological detection system, the NG-ADS continuously collects air samples, analyzes the samples for the presence of multiple biological pathogens, and automatically reports results to public health officials multiple times each day through a secure data network.
More than 20,000 samples were collected and analyzed during the recent field test in a variety of indoor and outdoor locations in a major city in the United States .
"There are concerns that our nation won't be ready to respond should a biological attack occur," said Dave Tilles, director of Homeland Security programs at Northrop Grumman's Electronic Systems sector.
"Early warning provided by an automated detection system such as the NG-ADS will allow the nation's public health and public safety officials to proactively manage the response to a biological event to reduce exposure and treat the affected population to minimize casualties."
Since the successful field test, additional improvements have been made to the NG-ADS to enhance the system's performance while reducing its life-cycle cost.
The proven, life-saving capability of the NG-ADS draws upon Northrop Grumman's decade long experience developing, testing, deploying, and operating bio-detection systems for the U.S. government and other customers.
PositiveID Corporation (OTCBB: PSID) recently reported it added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems ("MFS") subsidiary. The Company will utilize Dr. Smith's expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security ("DHS") for BioWatch Generation 3, a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America 's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. www.PositiveIDCorp.com.
http://www.investorideas.com/news/2012/main/08062.asp
Conclusive-Proof the PSID iglucose™ GlucoMeter is-listed on PSID's-website..
This product, the iglucose™ GlucoNeter, has not yet been cleared for sale in the United States by the FDA.
The iglucose GlucoMeter combines the functionality of a blood glucose meter with the wireless technology platform of the iglucose System to form an all-in-one device.
Please click HERE for more information.
http://www.positiveidcorp.com/products_iglucose_glucometer.html
About the iglucose GlucoMeter
The iglucose™ GlucoMeter, designed for individuals with diabetes, is a blood glucose meter that uses wireless technology to transmit glucose readings to a secure online database and automatically generates patient logbooks and trend reports.
Designated caregivers, family members and healthcare professionals can also access this data via the iglucose web-based diabetes management portal or their choice of email, text message or fax.
This seamless record keeping empowers individuals with diabetes to more actively manage their condition without the hassle of keeping daily manual logbooks and, more importantly, enables better collaboration and monitoring of glucose results to help improve diabetes self-care.
Key Device Features
Blood Sample size - 0.6 uL blood sample
Test Time - 5 seconds
Coding - Automatic
Memory Capacity - up to 500 readings
Meal Target - Pre/Post Meal Markers
Reminders - Supply reordering
Glucose Averages - 7-day, 14-day, or 30-day averaging
On/Off - Auto Shut off
Date and Time Settings - Automatic based on time zone
System Features
Multiple Communication Options - Users may select to have data sent via email, text message or fax.
Automated Reporting - Logbooks, trend reports, pie charts and histograms are available through the iglucose web-based portal.
Ability to Share Data - Blood glucose data can be tracked by the end user and authorized family members, caregivers or healthcare professionals through the secure, web-based patient portal.
Easy to Use and Set Up - Simply test your blood glucose and glucose data is transmitted to the iglucose diabetes management portal automatically.
Embedded Wireless Technology - iglucose uses cellular technology to automatically transmit readings from the iglucose glucometer to a secure central server.
Web Portal - Users and their selected family members, caregivers and healthcare professionals may access data via the web 24/7.
http://www.positiveidcorp.com/products_iglucose_glucometer.html
For more information contact:
Allison Tomek
Senior Vice President, Investor Relations & Corporate Communications
PositiveID Corporation
561.805.8044
atomek@positiveidcorp.com
I'm assuming PSID licensed Iglucose to SGMC..
As that's the only one of PSID's glucose related products, that are, currently, FDA approved, at this time, to my knowledge..
If PSID can fast track their EASY CHECK blood glucose breath testing meter to get FDA approved, licensed, manufactured, and bring to market with reliable sellers, before any of their competition does..
Assuming if PSID's EASY CHECK comes to market, within a reasonable period of time, and is the only provider of this technology, without having any competiton world wide..
If PSID had beat their Competitors to market ~ our share price would have been rewarded, accordingly, a long time ago..
IMO, PositiveID should have been more on the ball and gotten their two individual diabetes testing devices developed before their competition did..
1. PSID's GlucoMeter, hasn't even been FDA approved, yet..
2. And PSID's Iglucose device system, even though it was FDA approved.. Should have been licensed, manufacured and marketed for sales by reliable sellers, a long time ago, to generate revenue and increase share holder value..
PSID's two Competitors, IDEAL LIFE, and TELCARE are getting richer than rich, selling their own diabetes devices, like hot cakes..
IDEAl LIFE has been selling their own blood glucose device communications portal version, very similar to PositiveID's Iglucose device, for quite some time, now..
And PositiveID hasn' event sold any Iglucose device sytems, yet, to my knowledge..
TELCARE has been selling their own Blood Glucose Meter Testing Device, an all in one unit, that has a invasive blood glucose testing meter and a communication device combined, together, which is quite similar to PSID's GlucoMeter Device..
It's really too bad, for everyone concerned, that PSID wasn't able to beat out their Competiton and increase PSID share holder value, as we were expecting, when they had a chance to do so, on a timely manner..
Let's all hope for the best concerning PSID's BioWatch Generation 3 endeavor, that we're anticipating to increase share holder value, if PSID wins the stage 2 testin, Final Request For Proposal Contract..
And DHS decides to fully implement and deploy all 2500 units, as was proposed, during the next 5 years..
greaseyfingers Thursday, February 21, 2013 8:48:27 AM
Re: Peace-maker post# 5608 Post #5613 of 5664
PSID makes Iglucose, the GlucoMeter, and EasyCheck..
They are three individual, seperate PSID devices and function differently..
Iglucose is the communication portal device that works with certain blood glucose testing meters, that are compatable..
The PSID GlucoMeter is an all in one unit, that has a invasive blood glucose testing meter and communication device combined, together, like the one Telcare is already selling, a PSID Competitor..
EasyCheck is a Non-Invasive blood glucose breath testing meter, that if once approved, could be used with the Iglucose communication portal device..
Of these three individual PSID devices, as mentioned, to my knowledge, Iglucose is the only one that has been FDA approved, so far..
If you go to PSID's website you can read more about them in more detail, if you're interested in doing so..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84834494
mainebuys Friday, February 22, 2013 7:16:51 PM
Re: greaseyfingers post# 5726 Post #5728 of 5728
I am not often proven wrong. Very nice job of researching subject matter. Your related post on this subject should have reflected this degree of accuracy. So in your opinion what did they license to SGMC. IT is beyond me why they are making a GLUCCOMETER. This technology will soon be rendered obsolete, when EASYCHECK is released.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84919910
Website-link proving that PSID does-make the iglucose™ Glucometer.
This product, the iglucose™ Glucometer, has not yet been cleared for sale in the United States by the FDA.
The iglucose glucometer combines the functionality of a blood glucose meter with the wireless technology platform of the iglucose System to form an all-in-one device.
Please click HERE for more information.
http://www.positiveidcorp.com/products_iglucose_glucometer.html
About the iglucose glucometer
The iglucose™ glucometer, designed for individuals with diabetes, is a blood glucose meter that uses wireless technology to transmit glucose readings to a secure online database and automatically generates patient logbooks and trend reports.
Designated caregivers, family members and healthcare professionals can also access this data via the iglucose web-based diabetes management portal or their choice of email, text message or fax.
This seamless record keeping empowers individuals with diabetes to more actively manage their condition without the hassle of keeping daily manual logbooks and, more importantly, enables better collaboration and monitoring of glucose results to help improve diabetes self-care.
Key Device Features
Blood Sample size - 0.6 uL blood sample
Test Time - 5 seconds
Coding - Automatic
Memory Capacity - up to 500 readings
Meal Target - Pre/Post Meal Markers
Reminders - Supply reordering
Glucose Averages - 7-day, 14-day, or 30-day averaging
On/Off - Auto Shut off
Date and Time Settings - Automatic based on time zone
System Features
Multiple Communication Options - Users may select to have data sent via email, text message or fax.
Automated Reporting - Logbooks, trend reports, pie charts and histograms are available through the iglucose web-based portal.
Ability to Share Data - Blood glucose data can be tracked by the end user and authorized family members, caregivers or healthcare professionals through the secure, web-based patient portal.
Easy to Use and Set Up - Simply test your blood glucose and glucose data is transmitted to the iglucose diabetes management portal automatically.
Embedded Wireless Technology - iglucose uses cellular technology to automatically transmit readings from the iglucose glucometer to a secure central server.
Web Portal - Users and their selected family members, caregivers and healthcare professionals may access data via the web 24/7.
http://www.positiveidcorp.com/products_iglucose_glucometer.html
Important information to be aware of, for-all new-investors..
If PSID had beat their Competitors to market ~ our share price would have been accordingly rewarded, a long time ago..
IMO, PositiveID should have been more on the ball and gotten their two individual diabetes testing devices developed before their competition did..
1. PSID's GlucoMeter, hasn't even FDA approved, yet..
2. And PSID's Iglucose device system, even though it was FDA approved.. It should have been licensed, manufacured and marketed for sales by reliable sellers, a long time ago, to generate revenue and increase share holder value..
PSID's two Competitors, IDEAL LIFE, and TELCARE are getting richer than rich, selling their own diabetes devices, like hot cakes..
IDEAl LIFE has been selling their own blood glucose device communications portal version, very similar to PositiveID's Iglucose device, for quite some time, now..
And PositiveID hasn' event sold any Iglucose device sytems, yet, to my knowledge..
TELCARE has been selling their own Blood Glucose Meter Testing Device, an all in one unit, that has a invasive blood glucose testing meter and a communication device combined, together, which is quite similar to PSID's GlucoMeter Device..
It's really too bad, for everyone concerned, that PSID wasn't able to beat out their Competiton and increase PSID share holder value, as we were expecting, when they had a chance to do so, on a timely manner..
Let's all hope for the best concerning PSID's BioWatch Generation 3 endeavor, that we're anticipating to increase share holder value, if PSID wins the stage 2 testin, Final Request For Proposal Contract..
And DHS decides to fully implement and deploy all 2500 units, as was proposed, during the next 5 years..
greaseyfingers Thursday, February 21, 2013 8:48:27 AM
Re: Peace-maker post# 5608 Post #5613 of 5664
PSID makes Iglucose, the GlucoMeter, and EasyCheck..
They are three individual, seperate PSID devices and function differently..
Iglucose is the communication portal device that works with certain blood glucose testing meters, that are compatable..
The PSID GlucoMeter is an all in one unit, that has a invasive blood glucose testing meter and communication device combined, together, like the one Telcare is already selling, a PSID Competitor..
EasyCheck is a Non-Invasive blood glucose breath testing meter, that if once approved, could be used with the Iglucose communication portal device..
Of these three individual PSID devices, as mentioned, to my knowledge, Iglucose is the only one that has been FDA approved, so far..
If you go to PSID's website you can read more about them in more detail, if you're interested in doing so..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84834494
All of my PSID-shares are locked-in at $4.00 ever since, early, last summer of 2012..
Before, anyone here, ever suggested that everyone should be doing this, too..
PSID makes Iglucose, the GlucoMeter, and EasyCheck..
They are three seperate PSID devices and function differently..
Iglucose is the communication portal device that works with certain blood glucose testing meters, that are compatable..
The PSID GlucoMeter is an all in one unit, that has a blood glucose testing meter and communication device combined, together, like the one Telcare is already selling..
EasyCheck is a Non-Invase blood glucose testing meter, that if once approved, could be used with the Iglucose communication portal device..
Of these three PSID devices, as mentioned, to my knowledge, Iglucose is the only one that has been FDA approved, so far..
If you go to PSID's website you read more about them in more detail..
Iglucose is FDA approved, the PSID GlucoMeter hasn't-been FDA-approved, yet, to my knowledge..
These are two seperate PSID product devices..
You would compare it to PSID's GlucoMeter, not-Easycheck..
PSID information from January 16, 2013
Effective as of January 16, 2013, PositiveID Corporation, a Delaware corporation (the “Company”) entered into a Securities Purchase Agreement.
(the “Purchase Agreement”) with TCA Global Credit Master Fund, LP, a Cayman Islands limited partnership (“TCA”), pursuant to which TCA may purchase from the Company up to five million ($5,000,000) senior secured, convertible, redeemable debentures.
http://meshpress.com/stocks-in-news-simo-psid-nxpi-cab-mt/1232223.html
The PSID GlucoMeter isn't even FDA approved, yet, or anywhere near being licensed to be sold to people with diabetes..
Telcare's Diabetes Device is similar to PSID's GlucoMeter..
If you go to PositiveID's website you can see the difference between the PSID GlucoMeter and the PSID Iglucose device..
Telecare's Diabetes Device was The First Place Winner of the very World Famous 2012 Prestigious Gold Edison Award..
The Telcare Diabetes Device has already been FDA approved, licensed, and has been being sold for quite some time, now, to the many millions of people who have diabetes..
Here is the Video for the Telcare Blood Glucose Meter
http://telcare.com/support/videos/
How is this telecare device similar to our product?
The whole point of our product is that it is non-invasive...meaning no drop of blood is required. I looked over that video, and it seems that Telecare product needs blood...unless i am missing something
It looks like PSID may be losing out to their Competition..
The PSID GlucoMeter isn't even FDA approved, yet, or anywhere near being licensed to be sold to people with diabetes..
However, Telcare's Diabetes Device, similar to PSID's Glucometer was The First Place Winner of the very World Famous 2012 Prestigious Gold Edison Award..
The Telcare Diabetes Device has already been FDA approved, licensed, and has been being sold for quite some time, now, to the many millions of people who have diabetes..
Here is the Video for the Telcare Blood Glucose Meter
http://telcare.com/support/videos/